
Author Index to Volumes 44–50

- Aalders JG, 44:223
Abdelhay E, 47:275
Abe T, 49:219
Adhvaryu SG, 48:135
Advani SH, 50:89; 50:109
Aissaoui Z, 48:209
Akrad M, 50:189
Alberts KA, 48:101
Alumets J, 48:225
Amagasaki T, 50:149
Angelucci D, 50:277
Archidiacono N, 46:1
Armitage JO, 47:73
Asou N, 47:277
Atkin NB, 44:229;
 46:129; 49:281
Atkins L, 45:41
Aurias A, 45:55
Aventín A, 50:227

Babin P, 45:125
Babińska M, 49:259
Babonits M, 46:93
Babu VR, 48:83
Baczek NA, 45:179
Badia L, 45:1
Baer MR, 45:67
Baker MC, 44:229; 49:281
Bal S, 48:199
Balar DB, 48:135
Balderup B, 48:217
Balogh E, 44:119
Balsara BR, 50:89
Banks-Schlegel SP,
 45:101
Bardi G, 49:51
Barrios L, 49:107
Bartholdi MF, 50:231
Bartnitzke S, 44:253;
 46:55; 49:165; 50:161
Bauchinger M, 47:219;
 48:13
- Bauters F, 46:173
Becher R, 44:181
Beckett MA, 50:125
Belge G, 44:253
Bello MJ, 45:223
Ben-Bassat H, 49:241
Ben-Bassat I, 47:139,
 48:125, 48:279
Benet J, 46:251
Beneyto M, 45:1
Benitez J, 44:277; 46:281
Benn P, 48:75
Bennett J, 48:131
Benoit Y, 45:49
Berg SL, 44:55
Berger CS, 47:95; 47:179
Berger R, 44:69; 44:143;
 49:265; 50:53
Bergerheim USR, 49:125
Beris P, 44:271
Beris Ph, 46:157
Berkowicz M, 47:139;
 48:125, 48:279
Bernacer M, 44:277
Bernstein R, 50:153
Berrozpe G, 50:9
Bertness VL, 44:47
Beverstock GC, 48:179
Bhisey AN, 50:89
Bigner DD, 47:141
Bigner SH, 47:141
Bignon J, 49:37
Biörklund A, 44:209
Birch JM, 45:245
Bixenman HA, 46:135;
 49:137
Block AW, 50:171
Bojan F, 44:119
Bonfill X, 46:251
Boogaerts MA, 49:171
Bordes R, 50:227
Borek DA, 47:61
- Borman LS, 46:231
Bosga-Bouwer A, 50:103
Bosl GJ, 50:67
Bouts MJ, 47:1
Branco P, 49:103
Branda RF, 46:231
Brandt G, 44:253
Briault S, 45:125
Bridge JA, 47:61; 49:199
Brinck-Johnsen T, 47:227
Britton V, 47:265
Brizard A, 45:125
Brøgger A, 45:85; 47:69
Brothman AR, 47:135;
 49:277
Broun ER, 46:125
Brunet S, 50:227
Buist J, 44:217; 44:223;
 46:75
Bullerdiek J, 44:253;
 46:55; 49:165; 50:161
Bülow S, 50:139
Burgio GR, 45:137
Burvall K, 48:183
Butti G, 45:237
Byrd R, 49:277

Caballin MR, 44:193,
 50:9
Caballín MR, 46:251,
 49:107, 49:133
Calabrese G, 50:277
Calasanz MJ, 48:133
Calderone C, 44:61
Campagnoli E, 45:137
Campbell EW, 48:89
Caracino A, 50:277
Carter J, 48:255
Casalone R, 45:237;
 45:269; 45:273
Cascinelli N, 44:61
Caselitz J, 50:161

- Cassiman J-J, 45:217; 49:87; 49:171
 Castedo SMMJ, 44:223; 48:143; 49:103
 Castel V, 45:1
 Cavenee WK, 49:15
 Cedrone E, 46:271; 50:199
 Celli P, 48:39
 Cerny JC, 48:83
 Cervenka J, 50:265
 Chadduck WM, 47:89; 47:101
 Chaganti RSK, 50:67
 Chakrabarti S, 48:23
 Challinor PR, 45:261
 Champlin R, 49:177
 Chaparro M, 50:153
 Chase CL, 46:21; 50:119
 Chen D, 48:89
 Chen SJ, 44:69; 44:143
 Chen TR, 48:139
 Chen Y-C, 47:29
 Chen Z, 44:143
 Chisesi T, 48:39
 Chlecq C, 49:37
 Choi BH, 45:207; 50:153
 Chu D, 49:235
 Chuang S-M, 49:31
 Cianchetti E, 50:277
 Cigudosa JC, 48:133
 Coll MD, 44:193, 49:133
 Collin F, 48:281
 Collins VP, 49:125
 Collyns-d'Hooghe M, 48:209
 Colombies P, 44:275
 Columbano-Green LM, 48:255
 Cordova LM, 45:179
 Cosson A, 46:173
 Cossu L, 47:273
 Couturier J, 44:243; 45:55
 Couzigou P, 49:249
 Cowan JM, 50:125
 Cram LS, 50:231
 Creasy M, 45:261
 Crossen PE, 48:255
 Curless R, 44:263
 Curtis D, 45:93
 Dadabhoy KD, 50:89
 Dadley B, 50:171
 Daeschner CW III, 50:169
 Daghistani D, 44:263
 Dahl N, 46:115
 Dahlfors R, 44:1; 46:35
 Dal Cin P, 45:49
 Dale BM, 44:99
 D'Alessandro E, 45:231
 Dallorso S, 47:41
 Dalton A, 45:93
 Dam A, 44:217
 Darnaude MT, 45:35
 Dastugue N, 44:275
 Davies H, 47:249
 de Andrés L, 50:227
 DeBauche DM, 46:261
 Dębiec-Rychter M, 46:29
 Decker H-JH, 46:135
 De Cremoux H, 49:37
 Defferrari R, 48:35
 Dejana A, 48:35
 de Jong B, 44:217; 44:223; 46:75; 48:143; 50:103
 de la Chapelle A, 48:1
 Delannoy A, 48:49
 Delattre O, 44:107; 45:55
 Delfau MH, 48:209
 Delicado A, 45:35
 Della Porta G, 44:61
 Del Porto G, 45:231; 48:237
 De Miguel A, 44:193
 Deminatti M, 46:173; 48:209
 Demuyck H, 49:171
 De Potter C, 45:49
 Derré J, 44:69; 50:53
 Desablens B, 48:209
 de Torres ML, 45:35
 Devriendt K, 45:217
 Dewald GW, 45:179
 Diaz de Bustamante A, 45:35
 Di Cola M, 45:231
 Dietrich CU, 45:161
 Dittmar K, 48:75
 Di Virgilio C, 50:277
 Dmitrovsky E, 50:67
 Dobbin J, 47:275
 Domingo A, 50:227
 dos Santos SA, 49:25
 Drouin R, 48:265
 Dry J, 46:271; 50:199
 Duarte MHO, 49:25
 Dubé ID, 49:113
 Dufer J, 50:249
 Dutrillaux A-M, 44:107
 Dutrillaux B, 44:107, 44:131; 46:143, 49:37; 49:203
 Ebert W, 49:185
 Economopoulos T, 50:165
 Egoscue J, 44:193; 46:251; 49:107; 49:133; 50:9
 Einhorn S, 48:183
 Eisenmenger E, 47:83
 Elfving P, 46:191, 49:259
 Enero M, 48:101
 Erdel M, 49:185
 Escribano L, 49:225
 Ezpeleta I, 48:133
 Faed MJW, 48:259
 Fan S-X, 47:179
 Farber M, 47:155
 Farid NR, 44:119
 Felix CA, 44:47
 Feller A, 44:77; 50:15
 Fenaux P, 46:173; 48:209
 Ferre D, 45:197; 50:249
 Ferro T, 49:225
 Ferti-Passantonopoulou A, 49:271; 50:165
 Fisher C, 50:1
 Fleming S, 45:81
 Fletcher CDM, 48:31
 Flodérus U-M, 44:27; 45:63; 46:65
 Flury-Hérard A, 49:37
 Fonatsch C, 47:197
 Ford J, 46:201
 Ford JH, 44:99
 Fordyce R, 47:163
 Fossati G, 44:61
 Fotiou S, 49:51
 Foucar K, 45:179
 Fox MF, 44:229; 46:129
 Fraisse J, 48:281
 Franssila KO, 48:109
 Frisk B, 49:125
 Fruchtman S, 46:185
 Fryns J-P, 49:87
 Fujieda H, 48:169
 Fujita H, 49:117
 Fujita N, 49:69
 Fuster C, 49:107
 Gahrton G, 45:143; 48:183
 Gale RP, 46:107; 49:177
 Gambaro F, 49:75
 García de Miguel P, 45:35
 Garré ML, 47:41
 Garson OM, 46:201
 Gatti RA, 46:1
 Gaudray P, 49:143
 Gedde-Dahl T, 47:69
 Geleick D, 46:217
 Genescà A, 46:251

- Genuardi M, 49:229
Gerbault-Seureau M, 49:203
Ghidoni A, 49:75
Ghosh PK, 44:197; 44:203
Ghosh R, 44:197; 44:203
Ghosn C, 47:135
Gibson SH, 47:227
Gilliland G, 47:55
Giudici A, 45:237; 45:269; 45:273
Gödde E, 50:15
Goetz P, 45:139
Goolsby CL, 50:231
Goosen LS, 47:101
Gordon J, 46:89
Gorman PA, 46:71; 48:193
Goussot-J-F, 49:249
Grammatico P, 48:237
Granata P, 45:237; 45:273
Grandchamp B, 48:209
Granzow C, 48:23
Grepp C, 44:1
Grierson HL, 47:163
Grison O, 49:249
Grossman A, 48:75
Grote W, 44:75; 50:15
Groupe Français de Cytogénétique Hématologique, 44:169
Guedea F, 49:107
Guerrasio A, 46:243
Guilhot F, 45:125
Gullon A, 48:133
Guntur M, 44:197; 44:203
Gustavson K-H, 46:115
Gustavsson I, 46:115
Gusterson BA, 48:31
Hackbarth DA, 47:61
Hagemeijer A, 47:1
Hagmar L, 45:85
Hall AP, 49:103
Halme A, 48:1
Han T, 50:171
Hannan MA, 47:191
Hansen MF, 49:15
Hansteen I-L, 45:85
Harless J, 50:45
Harrington CI, 45:93
Harris M, 45:245
Harris RI, 45:261
Hartley AL, 45:245
Haupt R, 47:41
Haus O, 48:281
Havel G, 44:1
Heath DV, 50:169
Hecht BK, 46:9; 49:283
Hecht F, 44:37; 45:277; 45:279; 46:9; 46:133; 47:271; 49:137; 49:283; 141
Heerema NA, 46:41; 46:125
Heim S, 44:27; 44:209; 45:63; 45:85; 46:65; 46:191; 48:101; 48:119; 48:217; 48:225; 49:95; 49:259; 49:273
Helm G, 48:217
Heyner S, 47:155
Higuchi S, 47:277
Hild F, 47:197
Hill BT, 46:71
Himmler A, 44:77
Hobson EA, 47:101
Hochsattel R, 45:161
Högstedt B, 45:85
Hollema H, 44:223
Hoogsteden HC, 47:1
Horn T, 50:139
Horsman DE, 45:193; 45:249
Hossfeld DK, 44:15
Huber H, 50:189
Humphries JE, 44:187
Huret JL, 45:125
Hutter K-J, 44:253
Ichimaru M, 49:157; 50:149
Ikeda S, 49:157
Imanishi H, 49:219
Inaba T, 49:69
Inazawa J, 49:219
Ingelaere H, 45:49
Insel R, 46:271
Ishihara T, 45:13
Ishii K, 48:61
Ishiwata I, 49:117
Itoh K, 49:69
Itoyama T, 49:157; 50:149
Iwabuchi A, 45:73; 48:169
Iwabuchi H, 45:73
Iwahara Y, 48:61
Jacob AK, 45:67
Jacob G, 44:83
Jacob J-L, 48:265
Jani KH, 48:135
Jankowska J, 46:29
Jin Y, 44:27; 44:209; 49:95
Johansson B, 48:119
Johansson M, 48:225
Jones MC, 47:243
Jonveaux P, 49:265; 50:53
Jotterand-Bellomo M, 44:271; 46:157
Jouet JP, 48:209
Jubashi T, 49:157
Juhasz F, 44:119
Juliusson G, 45:143; 48:131; 48:183
Kadam PR, 50:89, 50:109
Kadota RP, 47:243
Kakati S, 48:275
Kalat M, 47:83
Kallman KD, 50:45
Kalousek DK, 45:193
Kałużewski B, 46:29
Kanda N, 48:229
Kaneko Y, 47:171; 47:277; 50:273
Kao YS, 45:265
Karlic H, 50:189
Kashima K, 49:219
Kato H, 49:117
Katz J, 45:207
Kazuma M, 48:229
Kees UR, 46:201
Kelsey AM, 45:245
Keltzel M, 47:89
Kerckaert JP, 48:209
Kerim S, 46:99; 46:243
Keur Dvd, 48:179
Khokhar MT, 47:249
Kiechle-Schwarz M, 47:95
Kirsch IR, 44:47
Kieer E, 50:97
Klein G, 46:93
Knogler W, 50:189
Knowles BB, 45:255
Knudsen L, 45:85
Knuutila S, 48:109
Kobayashi H, 47:171
Koeffler HP, 46:107
Kohn G, 49:241
Kohno S, 45:13
Kovanen PE, 48:109
Kowal-Vern A, 46:83; 50:31
Kraemer PM, 48:89; 50:231
Krespin HI, 45:131
Kristoffersson U, 46:191; 48:119
Krone W, 45:161
Krous HF, 47:243
Kubota K, 48:229

- Kujas M, 45:55
 Kurvink K, 50:207;
 50:265
 Kuse R, 44:15
 Kwan Y-L, 47:265
 Laï JL, 46:173; 48:209
 Lambert B, 45:85
 Lam-Po-Tang PRL, 47:47
 Laraña JG, 49:225
 Larsen JK, 50:139
 Laurence KM, 44:279
 Laureys G, 45:49
 Lawler SD, 47:249; 50:1
 Le Baron F, 46:173
 Le Coniat M, 44:69; 50:53
 Lee EC, 45:101
 Lee F-Y, 49:31
 Lemieux N, 48:265
 Lennert K, 50:15
 Leonard C, 44:131
 Leong SPL, 45:81;
 47:113; 49:235
 Leroy J, 45:49
 Lester EP, 47:131
 Li FP, 46:135
 Liautaud-Roger F, 50:249
 Libbus BL, 46:231
 Licheri S, 47:273
 Ligas C, 45:231
 Limon J, 46:191; 49:259
 Lin CC, 48:271
 Lin C-T, 49:31
 Lin D-T, 47:29
 Lin K-H, 47:29
 Lin M-T, 47:29
 Linnainmaa K, 45:85
 Lockhart LH, 50:169
 Lockwood DH, 44:37
 Löfvenberg E, 49:57
 Logan JA, 45:41
 London B, 49:113
 Longmire J, 48:89
 Longy M, 49:249
 Lopes JM, 49:103
 Lopez Pajares I, 45:35
 Lo Re ML, 45:231; 48:237
 Lothe RA, 47:69
 Loucheux-Lefebvre MH,
 48:209
 Lukeis R, 46:201
 Lukusa T, 49:87
 Lundgren R, 46:191;
 49:259
 Maddrey WC, 45:255
 Madhavi R, 44:197;
 44:203
 Malone M, 48:193
 Mamon Z, 47:139
 Mandahl N, 44:27;
 44:209; 45:63; 46:65;
 46:191; 48:101;
 48:119; 48:217;
 48:225; 49:95;
 49:259; 49:273
 Mandal AK, 44:279
 Mangelschots K, 45:49
 Mansberg R, 47:47
 Måansson B, 48:225
 Mariani T, 46:209
 Mark J, 44:1; 44:153;
 46:35; 47:141
 Mark-Vendel E, 48:281
 Martuza RL, 45:41
 Marynen P, 45:217
 Mascarello JT, 47:243
 Maseki N, 47:171
 Maserati E, 45:137
 Massaad L, 44:131
 Masuda M, 48:229
 Matsuda I, 47:277; 50:273
 Matter A, 46:217
 Mauhin C, 49:249
 Mayr B, 47:83
 McBride OW, 44:47
 McCombs JL, 50:169
 McConnell TS, 45:179
 McCormick C, 45:265
 McKeithan TW, 49:219
 Mecucci C, 48:49; 48:131;
 49:171
 Medchill M, 47:179
 Meeker T, 48:183
 Melnyk A, 46:83; 50:31
 Merchant AA, 50:109
 Mertens F, 48:119
 Messier P-E, 48:265
 Meulepas E, 49:87
 Meyer K, 46:55
 Meyne J, 48:271
 Mezger J, 48:13
 Michaux JL, 46:99
 Milatovich A, 46:41
 Miles BJ, 48:83
 Milot J, 48:265
 Minamihisamatsu M,
 45:13
 Minelli E, 45:237; 45:269;
 45:273
 Miozzo M, 44:61
 Miró R, 46:251; 49:107;
 50:9
 Misawa S, 49:69; 49:219
 Mitchell ELD, 47:107
 Mitelman F, 44:27;
 44:209; 45:63; 45:85;
 46:65; 46:191;
 48:101; 48:119;
 48:225; 48:217;
 49:95; 49:259; 49:273
 Miura I, 48:203
 Miyoshi I, 48:61
 Mizoguchi H, 48:229
 Mizui K, 50:75
 Modesti A, 48:237
 Mollevanger P, 48:179
 Moltó E, 50:227
 Monica K, 50:207
 Montaldi A, 48:39
 Moreau L, 46:89
 Moreno S, 45:223
 Moret M, 47:1
 Morgan R, 44:47; 49:15
 Morizot DC, 50:45
 Morrell D, 46:21; 50:119
 Morris Jones PH, 45:245
 Mosna G, 49:75
 Moyzis RK, 48:271
 Mrózek K, 49:259
 Mugneret F, 48:281
 Muis N, 50:103
 Muleris M, 44:107;
 46:143
 Müller H, 46:217
 Munoz SJ, 45:255
 Murakami S, 49:69
 Murakami T, 47:277
 Murty VVVS, 50:67
 Naeim F, 49:177
 Nairn RS, 50:45
 Najfeld V, 46:185
 Nakagawa H, 49:219
 Nakagawa M, 49:69
 Nakamura H, 49:157;
 50:149
 Nakanishi S, 49:69
 Nash R, 50:1
 Navarro JL, 49:225
 Navarro S, 45:121
 Nebraska Lymphoma
 Study Group, 47:73
 Nedoszytko B, 49:259
 Neff JR, 47:61; 49:199
 Neri G, 49:229
 Nespoli L, 45:137
 Neuman Y, 48:125
 Ng JP, 45:261
 Nicoletti B, 50:35
 Niiya K, 48:61
 Nikiforakis E, 49:271
 Nilbert M, 44:27; 45:63;
 48:217
 Nilsson P-G, 48:119
 Nishida K, 49:219

- Nishigaki H, 49:69; 49:219
Nishio A, 49:69
Noguera R, 45:121
Noll WW, 47:227
Nomura Y, 48:229
Noordhoek L, 50:103
Nordenson I, 45:85; 49:57
Nordic Study Group on the Health Risk of Chromosome Damage, 45:85
Nordquist A, 46:35
Noumoff JS, 47:155
Nowell PC, 46:89

Obara Y, 50:75
Odriozola J, 49:225
Ohtsuki Y, 48:61
Ohyashiki JH, 45:73; 48:169
Ohyashiki K, 45:73; 48:169
Okada M, 48:229
Oku N, 49:69
Okuda T, 49:219
Olah E, 44:119
Olschwang S, 44:107
Oosterhuis JW, 44:217; 44:223; 46:75; 48:143
Örndal C, 48:225; 49:95
Orth G, 44:243
Orts A, 45:1
Oyarzabal FJ, 48:133

Palau F, 45:1
Palka G, 50:277
Palmer CG, 46:41
Panani AD, 49:271; 50:165
Panayotopoulos N, 49:51
Pandis N, 49:51
Parlier V, 44:271; 46:157
Parr A, 44:181
Pasino M, 47:41
Pasquali F, 45:137
Paterlini P, 45:231
Patey M, 50:249
Pati A, 45:261
Patterson EJ, 47:55
Paweltz N, 50:57
Pedron S, 47:179
Pejovic T, 46:65; 49:95
Peltomäki P, 48:1; 48:109
Pereira MSO, 47:275
Perez de Oteyza J, 49:225
Perez-Sirvent ML, 45:1
Perucca D, 49:143
Peter M, 45:55

Peter W, 49:185
Peters GB, 44:99
Petite J, 44:271
Pettengill OS, 47:227
Pettersson U, 46:115
Phebus CK, 44:55
Philippon J, 45:55
Pierotti MA, 44:61
Pinkerton PH, 49:113
Piras A, 46:209
Pirruccello S, 47:163
Ploem JE, 48:179
Porta F, 45:137
Portensoso P, 45:269
Porzucek L, 50:207
Potter AM, 44:83
Potter CW, 44:83
Potter M, 46:93
Powell I, 50:97
Powles R, 47:249
Prieto F, 45:1
Prieur M, 44:131
Pris J, 44:275
Pritchard J, 48:193
Privitera E, 49:75
Prokocimer M, 49:241
Pujol-Moix N, 50:227
Purtilo DT, 47:163

Qiu J-Y, 44:181
Quaglino D, 45:231


Rainaldi G, 46:209
Ramesh KH, 44:37
Ramot B, 47:139; 48:125; 48:279
Raptis S, 49:271; 50:165
Ray M, 48:199
Rechavi G, 48:125; 48:279
Rees RC, 44:83
Reeves BR, 50:1
Rege-Cambrin G, 46:99; 46:243
Regenass U, 46:217
Reifinger M, 47:83
Remvikos Y, 44:107
Resau J, 48:203
Resnitzky P, 47:139
Reuterwall C, 45:85
Rey JA, 45:223
Richer C-L, 48:265
Rivas C, 46:281
Roberts CG, 48:53; 48:243
Roberts SH, 44:279
Robertson J, 48:259
Rocchi M, 46:1
Rödjer S, 48:67
Roloson GJ, 47:101

Romain DR, 48:255
Romano J, 50:171
Romeo G, 46:1
Rommel B, 49:165
Rootman J, 45:249
Rosenthal DS, 47:55
Rosner E, 47:139; 48:125; 48:279
Rosso C, 46:243
Rouleau G, 45:55
Rouse BM, 50:169
Rune C, 46:115
Rydholm A, 48:101; 48:217; 49:273

Sacchi N, 46:1
Sackey K, 47:191
Sadamori N, 49:157; 50:149
Sage RE, 44:99
Saglio G, 46:99
Sakurai M, 47:171
Sala E, 49:75
Salmon R-J, 44:107; 46:143
Salomaa S, 45:85
Salvador J, 50:9
Salvidio E, 48:35
Sandberg AA, 44:47; 45:67; 45:81; 46:135; 47:95; 47:113; 47:179; 49:15; 49:199; 49:235; 50:171
Sandros J, 44:153
Sanford KK, 46:139
Sanger WG, 47:73; 47:163
Sansone R, 47:41
Santos M, 46:281
Saryusz-Wolska H, 46:29
Sasagawa I, 49:157; 50:149
Sasi R, 48:271
Sastre-Garau X, 44:243
Sato T, 50:75
Satyaswaroop PG, 47:155
Saura R, 49:249
Sawyer JR, 47:89; 47:101
Scalise A, 46:185
Scaravaglio P, 46:99
Scarpa S, 48:237
Schlegelberger B, 44:77; 50:15
Schleger W, 47:83
Schloto W, 46:55; 49:165
Schmidt C-G, 44:181
Schmidt PM, 46:157
Schneider-Maunoury S, 44:243

- Schoenwald M, 45:125
 Schouler L, 49:249
 Schouten HC, 47:73
 Schraffordt Koops H, 46:75
 Schreck RR, 46:107
 Schroeter D, 50:57
 Schwartz C, 50:199
 Schweiger P, 47:83
 Schweizer D, 50:189
 Secker-Walker LM, 49:1
 Seizinger BR, 45:41
 Senn JS, 49:113
 Seruca R, 49:103
 Sessarego M, 47:41; 48:35
 Sfikas K, 49:51
 Shah PM, 48:135
 Sharma P, 47:47
 Sheer D, 46:71; 48:193
 Shen V, 50:153
 Shen W-PV, 45:207
 Shimazaki C, 49:69
 Shiraishi Y, 50:175
 Shlomai Z, 49:241
 Sigut D, 47:191
 Silberstein L, 46:89
 Silva MLM, 47:275
 Silva S, 46:93
 Simi P, 45:237
 Simi S, 46:209
 Simon D, 45:255; 47:155
 Simon M-P, 49:143
 Sivakumaran M, 48:259
 Skare J, 47:163
 Skerfving S, 45:85
 Skinnider L, 45:131
 Skuse GR, 46:271; 50:199
 Smith BP, 47:191
 Smith M, 45:207
 Smith MA, 48:31
 Smith S, 48:31
 Smith SD, 44:47
 Soares LRM, 49:25
 Solé F, 44:193; 49:133
 Solero CL, 45:237
 Söregi G, 50:189
 Sorsa M, 45:85
 Souza JM, 47:275
 Sozzi G, 44:61
 Sparkes RS, 46:107; 49:177
 Speleman F, 45:49
 Spiess E, 49:185
 Spiga I, 49:75
 Sreekantaiah C, 45:67; 45:81; 47:113; 47:179; 49:235
 Sroka H, 45:249
 Stallings R, 48:89
 Stanley WS, 46:261
 Stary J, 45:139
 Steiner M, 50:231
 Stejskalova E, 45:139
 Stella M, 48:39
 Stellan B, 49:125
 Stenman G, 44:153; 46:35
 Stenzky V, 44:119
 Stern C, 46:55
 Stracca-Pansa V, 48:39
 Strauss PG, 47:219
 Stul MS, 49:171
 Stuppia L, 50:277
 Subias A, 49:107
 Suciu S, 44:15
 Sugiyama H, 46:93
 Sun G, 46:107; 49:177
 Sureda A, 49:225
 Surti U, 47:95
 Svendsen LB, 50:139
 Svensson R, 50:45
 Swift M, 46:21; 50:119
 Swolin B, 48:67
 Szepetowski P, 49:143
 Tabak D, 47:275
 Tada M, 48:229
 Taguchi H, 48:61
 Takai S, 46:139
 Takeuchi T, 48:61
 Tanaka S, 49:219
 Taniwaki M, 49:69; 49:219
 Tantravahi R, 47:55
 Tanzer J, 45:125
 Tarbell N, 50:125
 Tarnow-Mordi WO, 48:259
 Tarone RE, 46:139
 Tarrida N, 44:193
 Tattersall MHN, 48:53; 48:243
 Tauchi T, 45:73
 Tebbi CK, 48:275
 Tedeschi B, 50:35
 te Meerman GJ, 48:143
 Terryberry S, 50:199
 Tesmer J, 48:89
 Testa JR, 48:203
 Teyssier J-R, 45:197; 50:249
 Tharapel SA, 47:131
 Thomas G, 44:107; 45:55
 Thorup J, 50:139
 Tien H-F, 47:29; 49:31
 Todd AS, 48:259
 Tokunaga S, 49:157; 50:149
 Toledano SR, 44:263
 Tomiyasu T, 48:203
 Tone LG, 49:25
 Torhorst J, 46:217
 Torrabadella M, 49:139
 Toyama K, 45:73; 48:169
 Trefz G, 49:185
 Treleaven JG, 50:1
 Triche TJ, 45:121
 Tricot G, 46:125
 Troy K, 46:185
 Truglio F, 45:137
 Tserkezoglou A, 49:51
 Tsuchiya H, 47:277; 50:273
 Tsuda S, 49:219
 Tuerlings J, 50:103
 Turc-Carel C 48:281
 Tyrkus M, 50:97
 Ura Y, 49:69
 Urata Y, 49:219
 Valente AN, 47:275
 Valiente A, 44:277
 Vallespí T, 49:139
 van den Berg E, 44:217
 Vandenberghe EA, 48:49
 Van Den Berghe H, 45:49; 45:217; 46:99; 46:243; 48:49; 49:87; 49:171
 van der Kwast ThH, 47:1
 Van Drunen E, 47:1
 Van Dyke DL, 48:83
 Vanni R, 47:273
 Vatteroni L, 46:209
 Vecchione D, 44:69; 50:53
 Ventrone CH, 46:231
 Verhoef GEG, 49:171
 Vermeij B, 44:217
 Vernole P, 50:35
 Versnel MA, 47:1
 Vespiagnani M, 48:39
 Vial R, 45:265
 Viegas-Péquignot E, 49:37
 Vig BK, 50:9:57
 Volk MS, 48:275
 Vollrath M, 50:161
 Vos A, 44:217; 44:223; 46:75; 48:143
 Wada E, 48:229
 Wahlin A, 49:57
 Wake N, 49:117
 Walter BN, 45:207
 Wang C-H, 47:29

- Wang HC, 45:131
Wang N, 46:271; 50:199
Wang SY, 45:131
Watmore AE, 44:83
Wedell B, 44:1
Weh HJ, 44:15
Wei S, 46:1
Weichselbaum RR,
 50:125
Weinberg M, 44:253
Weinfeld A, 48:67
Weinstein M, 48:75
Weisenburger DD, 47:73
Weiss L, 48:83
Weiss R, 48:75
Wendehorst E, 44:181
Wenger SL, 44:55
Wennerberg J, 44:209
Werner E, 47:135; 49:277
Wessels H, 48:179
Westin J, 48:67
Whang-Peng J, 45:101
Wheby MS, 44:187
Whelan R, 46:71
White L, 47:265
White VA, 45:249
Wiener F, 46:93
Wiley JE, 50:231
Willén H, 44:27; 45:63;
 46:65; 48:101;
 48:217; 49:95; 49:273
Williams G, 48:199
Williams GJ, 47:249
Willoughby MLN, 46:201
Wilmanns W, 47:219
Wiltshaw E, 50:1
Wittekind C, 50:161
Woessner S, 44:193;
 49:133
Wormsley S, 49:177
Wurster-Hill DH, 47:227
Wyandt H, 47:163
Xiao H, 48:275; 50:171
Yamada H, 49:117
Yamada Y, 49:157
Yamaguchi K, 47:277
Yao E, 49:157
Yaseen NY, 44:83
Yip M-Y, 47:47; 47:265
Yokoyama Y, 47:277
Yongshan Y, 46:261
Young R, 50:153
Young RF, 45:207
Zafaraullah KZ, 50:89
Zafrani B, 49:203
Zandecki M, 46:173
Zech L, 49:125
Zhang J, 45:217
Zitzelsberger H, 47:219
Zollino M, 49:229
Zumel RM, 45:35



Subject Index to Volumes 44-50

- Acrocentric chromosomes
interconnections, 50:207
NOR, 50:207
satellites, 50:207
variant NOR, 50:207
- Acute erythroleukemia (M6)
childhood, 49:25, 28 (Table)
chromosome analysis in the differential diagnosis, 49:139; 50:89
chromosomes in, 48:67; 49:25; 50:89
MAKA pattern in, 50:89
secondary, 48:67
- Acute leukemia (AL)
biphenotypic, 47:265
complex chromosome changes and congenital anomalies in a baby born to a mother treated for AML, 50:169
ets-1 transposition, 50:199
hybrid with t(8;21), 49:177
in hydroxyurea-treated patients, 49:57
t(11;19) and biphenotypic, 50:199
+4 in biphenotypic, 47:265
- Acute lymphoblastic leukemia (ALL)
bcr in Ph+ ALL, 47:29
benzol and ALL, 49:133
biological importance of chromosome changes, 49:1
BMT in, 45:137; 49:249
breakpoint characterization of t(14;14), 44:47
cell line of pre-B ALL, 46:201
chromosome changes in, 44:47, 69, 143, 45:137; 46:201; 47:29, 249; 48:229; 49:1, 50:31
clinical aspects, 49:1
cytogenetics and transplantation, 45:137
favorable prognosis in children with hyperdiploidy, 50:273
hyperdiploidy and prognosis, 50:273
in XYY male, 49:215
late-appearing Ph, 48:35
Philadelphia-positive, 44:143; 47:29, 48:35; 49:1
ploidy in, 49:1
prognosis and chromosomes, 49:1
recurrence after BMT, 47:249
Rt locus in, 49:15
T-cell ALL cell line, 49:241
- T-cell type, 44:47, 69; 48:229; 49:1, 69, 241; 50:31
t(1;8) in T-ALL, 50:31
t(4;11) in carcinogen exposed patient, 49:133
t(6;9)(p32;q34) and +13, 45:139
t(8;14)(q24;q11) in T-ALL, 49:69
t(14;14)(q11.2;q32) in T-ALL, 44:47
t(16;20) in cell line (T-ALL), 49:241
translocations in, 46:201, 47:29; 49:1, 69; 50:31
6, 7, 9, 12 and 14 in T-ALL, 44:69; 48:229
- Acute megakaryoblastic leukemia (M7)
cytogenetic findings, 48:119
translocations in, 48:119
21 and 22, 48:119
- Acute monocytic (monoblastic) leukemia (M5)
chromosome changes in, 45:1; 47:249
chromosomes in, 46:99
i(11q) in M5a, 48:61
in children, 45:1
multiple clones, 47:171
9h in, 46:99
t(3;13) in, 49:277
unrelated clones, 47:171
11q23 in, 45:1
- Acute myeloblastic leukemia (M1)
chromosomes in, 47:139; 48:67
secondary, 48:67
t(16;21) in, 47:139
- Acute myeloblastic leukemia (M2)
chromosomes in, 46:185; 48:67; 50:103, 149
del(2)(p23) in, 46:185
secondary, 48:67
t(8;21) appearance, 50:149
8q22 involved, but not 21q22, 50:103
- Acute myelomonocytic leukemia (M4)
after 21 years of radon exposure, 48:125
chromosome changes, 45:1, 69, 261; 47:249; 48:125, 255, 50:103, 165
in children, 45:1
novel translocations, 44:99; 45:67, 50:165
radon induced?, 48:125
secondary, 50:165

- t(1;3) in secondary, 50:165
 t(1;6)(p12;p23), 45:67
 t(2;14) as sole change, 48:255
 t(3;21)(q26-27;q22) and
 t(15;21)(q21-22;q22) in ANLL, 44:99
 t(11;13) and 7q-, 45:261
 translocations in, 45:1, 69; 48:125, 255;
 50:165
 5q-, 5q- in M4 following MDS, 48:279
 8q22 involved, but not 21q22, 50:103
 11q23 in, 45:1
 21q22 in ANLL, 44:99, 50:103
- Acute nonlymphocytic leukemia (ANLL)**
 APL (M3), 47:41; 50:109
 BMT and recurrence, 47:249
 chromosome changes, 44:99, 143, 169,
 275; 45:1; 46:173; 47:139, 171, 249;
 48:61, 67, 255; 50:103, 109
 chromosomes in cyopreserved cells,
 45:179
 del(2)(p23) in M2, 46:185
 in children, 45:1
 in M4, 44:99; 45:1, 261; 48:255; 50:103
 in M5, 45:1; 47:171; 48:61, 49:277
 MDS and ANLL, 44:15; 46:173; 47:171
 multiple clones, 47:171
 neonatal in Down syndrome, 47:135
 pentasomy 21q in AL in Down
 syndrome, 47:135
 Ph-positive, 44:143
 secondary, 44:275; 46:173; 48:67; 49:57;
 50:165
 t(1;6)(p12;p23), 45:67
 t(3;13) in, 49:277
 t(8;21) in, 44:169; 50:149
 t(16;21) in, 47:139
 unrelated clones, 47:171
 use of G-CSF, 47:277
 +4 in undifferentiated AML, 45:265
 11q23 in, 45:1
 21q22 in, 44:99, 50:103
- Acute promyelocytic leukemia (M3)**
 chromosomes in, 45:193; 47:41; 50:109
 disappearance of Ph in relapse, 47:41
 Ph+ APL, 47:41; 50:109
 promyelocytic blast phase of Ph+ CML
 and t(15;17), 50:109
 Robertsonian translocation, 45:193
 Rt locus in, 49:15
 secondary, 47:41
 t(8;21) and t(9;22) in, 47:41
 t(15;17) in blast phase of Ph+ CML,
 50:109
- Adenolymphoma; see Warthin's tumor**
- Adenoma**
 chromosome changes in, 44:153
 parathyroid, 48:217
 pleomorphic of salivary gland, 44:153;
 46:55; 49:165
- polyps of colon, 49:249; 50:139
 renal, 49:125
 thyroid, follicular, 44:119, 217
- Angiofibroma**
 chromosomes in, 45:161
 in tuberous sclerosis, 45:161
- Angioimmunoblastic lymphadenopathy
 (AILD)**
 chromosome changes in, 44:77; 50:15
 four different clones in, 44:77
 inv(14)(q11q32) in, 44:77
 stepwise chromosome changes, 50:15
- Askin tumor**
 chromosome changes in, 47:89
 effects of radiation, 47:89
 t(11;22) in, 47:89
- Astrocytoma**
 anaplastic, 47:141
 chromosomes, 47:101, 141
 low-grade, 47:141
 molecular studies in, 47:141
 pontine, 47:101
 1q trisomy in, 47:101
- Ataxia-Telangiectasia (AT)**
 cancer in, 46:9, 21, 133; 50:119
 cancer in predisposition in
 heterozygotes, 46:21; 50:119
 carrier detection, 46:139
 complications of AT, 46:9, 21
 history of AT, 46:9
 mapping of 11q23, 46:1, 133
 molecular studies in, 46:1
 neoplasms in AT, 46:9, 21, 133; 50:119
 11q23 in, 46:1
- Atherosclerosis**
 chromosomes in plaque, 47:273
 plaque, 47:273
 +7 in plaque, 47:273
- Basal cell carcinoma**
 cytogenetic studies, 49:281
- B-cell disorders**
 ALL, 49:1
 chromosomes in, 46:89
 cold agglutinin disease, 46:89
 lymphoma with t(14;19)(p32.3;q13.1),
 49:219
- B-cell growth factor (BCGF)**
 effect on normal and neoplastic
 lymphocytes, 48:109
 effects, 48:109
 in lymphoma, 48:109
 proliferative effects, 48:109
- BCR-ABL rearrangements**
 chimeric transcripts, 48:209
 in acute leukemia, 44:143; 47:29
 in ALL, 44:143; 47:29
 in ANLL, 44:143
 in CML, 44:143, 277; 48:75, 209

- in masked Ph, 47:219
in Ph+ ALL, 47:29
in Ph+ CML in child, 44:277
in Ph+ CML in treated HD, 49:171
variant Ph, t(22;22), 48:209
- Benign tumors**
adenoma of thyroid, 44:119, 217; 50:249
chromosomes in, 44:1; 46:115; 47:95, 179; 50:249
dermoid of ovary, 49:95
leiomyoma, uterine, 44:1; 45:63, 47:95, 179
lipoma, 45:81; 47:113; 48:281, 49:235
meningiomas, 45:41, 237, 273; 47:141
neurinomas, 45:55
neurofibromatosis, 45:245
ovary, 44:223; 46:115; 48:243
salivary gland, 44:153; 46:35, 55
teratoma of ovary, 46:115
- Bladder tumors**
chromosome changes in, 46:129; 49:143; 50:9, 97
chromosome instability in cancer patients, 49:107
lymphocyte abnormalities, 49:107
marker chromosomes, 50:97
molecular genetics of carcinomas, 49:143
sex chromosome loss and prognosis, 50:97
-X and -Y and disease course, 50:97
5q- as only change in cancer, 46:129
+7 as a primary event, 50:1
- Blast crisis**
in Ph+ CML, 48:133; 50:109
lymphoid, 48:133
t(15;17) in promyelocytic, 50:109
-7 and dms, 48:133
- Bloom syndrome**
cytogenetic and immunologic aspects, 50:175
lymphoblastoid cell lines, 50:175
SCE in, 50:175
- Bone marrow**
cytogenetic studies in recurrence after grafts, 47:249
Hodgkin disease, 50:1
mastocytosis, 48:13
metastasis in neuroblastoma, 45:131
transplantation, 45:137; 46:83
- Bone marrow transplantation (BMT)**
allogenic, 47:55
autologous, 45:137
cytogenetic studies in recurrences, 47:249
cytogenetics in, 45:137; 46:83; 47:55, 249
in CML, 46:83; 47:55
- leukemic recurrence in recipients of allografts, 47:249
MRD, 45:137
- Book reviews**
The Life and Times of Dr. Thomas Hodgkin, 49:283
- Brain tumors**
Askin tumor, 47:89
astrocytoma, 47:101; 47:141
classification, 47:141
ependymoma, 47:141
glioblastoma, 47:141
medulloblastoma, 47:141
meningiomas, 45:41; 47:141
neurinomas, 45:55
oligodendrogloma, 47:141
pontine astrocytoma, 47:101
-Y in meningioma, 45:41
- Breast**
cancer, 46:217; 47:107; 49:203
cell lines, 46:271
cytogenetics of cancer, 46:217; 47:83, 107; 49:203
dic(5;11) in male cancer, 47:107
male cancer, 47:107
paradiploid cases, 49:203
SCE in leukocytes of girl with breast cancer, 44:203
tumor in dog, 47:83
two identical active X chromosomes, 46:271
- Burkitt lymphoma**
American (stage II), 48:275
chromosomes in, 48:275
47,XY,+20,t(8;14) in, 48:275
- Cancer risk**
changes in lymphocytes and, 45:85; 49:107
chromosomal aberrations and, 45:85
chromosome changes and bladder cancer, 49:107
cytogenetic endpoints and, 45:85
in AT, 46:9
in heterozygotes of AT, 46:21
micronuclei and, 45:85
Nordic Study Group Report, 45:85
sister chromatid exchange (SCE) and, 45:85
- Canine tumor**
cytogenetics of mammary tumor, 47:83
mammary, 47:83
- Carcinoma in situ**
chromosomes, 46:75
of testis, 46:75
- Cell lines**
adenocarcinoma of lung, 49:185
adenomas, pleomorphic, 46:55
brain tumors, 47:141

breast cancer, 46:271
 Chinese hamster cell lines, 46:209, 231
 effect of conditioned media, 46:107
 effects of retinoid-acid on melanoma cell line, 46:261
 esophageal cancer, 45:101
 germ cell tumors, 50:67
 Hirosaki sarcoma (rat), 50:75
 human-hamster hybrid, 48:89
 human sarcomas (radiation-induced), 50:125
 karyotype evolution in cell line, 50:231
 karyotypes of lung cancer lines, 49:185
 Krukenberg tumor, 46:71
 melanoma cell lines, 46:261; 48:237
 nasopharyngeal cancer, 49:31
 neuroblastoma, 45:131
 ovarian of Chinese hamster, 46:231
 pre-B ALL line, 46:201
 salivary adenoma developing a carcinoma, 44:253
 SK-UT-1B line (uterine leiomyosarcoma) is diploid, 48:139
 squamous cell carcinoma of lung, 49:185
 SV40-transformed fibroblasts, 50:231
 T-ALL with t(16;20), 49:241
 tumorigenic human cell line, 50:231
 vulvar intraepithelial lesion, 44:243

Centromere
 dicentric, 50:57
 early replication of repetitive DNA, 50:57
 inactive centromeres, 50:57
 separation, 50:57

Cervical cancer
 chromosome changes in, 44:229
 1,3,4,5,11,14 and 17 in, 44:229

Childhood
 ANLL, 45:1
 CMMoL and chromosome changes, 44:131
 erythroleukemia, 49:25
 leukemia treated and effects of chemotherapy in progeny, 50:169

Chinese hamster
 cell lines, 46:231, 217
 chromosome changes in cell lines, 46:231
 fragile sites in cell lines, 46:217
 hamster-human hybrid cell line, 48:89
 nutritional folate-deficiency, 46:231
 ovary cell lines, 46:231

Chondrosarcoma
 chromosome changes in, 45:207
 molecular analysis, 45:207
 myxoid, 45:207
 10 and 22 in, 45:207

Chromosome changes
 in acute leukemia, Ph+, 44:143
 in AILD, 44:77; 50:15
 in ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
 in AML, 44:169; 47:139; 50:103
 in ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107, 173; 47:139, 171, 249; 48:119; 49:115, 277
 in APL, 47:41
 in Askin tumor, 47:89
 in bladder cancer, 49:143, 50:9
 in brain tumors, 47:141
 in breast cancer, 46:217; 47:107; 49:203
 in cervical cancers, 44:229
 in CIS of testis, 46:75
 in CLL, 45:143; 50:171
 in CML, 44:55, 143, 181; 45:13, 193; 46:83, 107; 47:55, 197; 48:75, 209; 49:15
 in CMMoL, 44:15, 131; 46:99, 173
 in cold agglutinin disease, 46:89
 in colon polyps, 49:249
 in dermatofibrosarcoma, 49:199, 273
 in endometrial tumors, 46:1
 in erythroleukemia, 50:89
 in esophageal cancer, 45:269
 in esophageal cancer (cell lines), 45:101
 in Ewing sarcoma, 47:61, 89
 in fibrosarcoma, 48:193; 49:199, 273
 in germ cell tumors, 50:67
 in Hodgkin disease, 50:1
 in kidney tumors, 45:197
 in large bowel cancer, 44:83; 44:107; 46:143
 in leiomyomas, 44:1; 45:63; 47:89, 179; 49:51
 in lipoma, 45:81; 47:113; 49:235
 in liver tumor, 47:243
 in lung tumors, 48:203; 49:37, 95, 185
 in lymphoma, 44:279; 45:125, 231; 46:107; 47:73; 48:39; 49:219; 50:53
 in MDS, 44:15, 27, 187; 45:73, 193; 46:107, 125, 157, 173, 243; 47:171, 275; 49:113
 in melanoma, 44:61; 48:237
 in meningioma, 45:41, 237, 273
 in mesothelioma, 46:135; 47:1
 in M2, 46:185
 in M3, 45:193; 50:109
 in M4, 44:99; 45:261; 50:103, 165
 in M5, 46:99
 in M7, 48:119
 in neurinomas, 45:55
 in osteosarcoma, 45:121; 50:125
 in ovarian tumors, 44:223; 45:223; 46:65, 71, 115; 48:53, 243; 49:95, 50:67, 189

- in Philadelphia-positive acute leukemia, 44:143; 47:29
- in preleukemia, 49:15
- in progeny of mother treated for AML, 50:169
- in prostate cancer, 48:83
- in RA, 44:15; 46:157, 173
- in radiation exposure, 45:13
- in radiation-induced sarcomas, 50:125
- in RAEB, 44:15; 46:125, 157, 173
- in RAEB-t, 44:15; 46:157, 173
- in RARS, 44:15, 46:157
- in renal cell carcinoma, 45:197
- in salivary gland tumors, 44:153; 46:35, 55; 50:161
- in secondary leukemia, 44:275; 45:1; 46:173; 48:67, 175; 49:57, 171; 50:165
- in secondary MDS, 46:173
- in squamous cell carcinoma, 44:209; 47:131; 49:95
- in T-ALL, 44:47, 69; 48:229; 49:1, 69; 50:31
- in teratomas, 46:115
- in testis, 46:75; 48:1, 143; 50:67
- in thyroid tumors, 49:44, 199, 217; 47:227; 50:249
- in tuberous sclerosis, 45:161
- in uterine sarcomas, 44:27; 47:89; 48:217
- in uterine tumors, 46:1; 50:189
- in uveal melanoma, 45:249
- in Warthin's (adenolymphoma) tumor, 46:35
- in Wilms tumor, 45:35
- multiple clones in ANLL and MDS, 47:171
- unrelated clones in ANLL and MDS, 47:171
- Chromosome instability**
 - human-hamster hybrids, 48:89
 - lymphocytes of bladder cancer patients, 49:107
 - SCE and, 48:89
 - Trans-acting factors, 48:89
- Chromosomes**
 - 1 in cervical cancers, 44:229
 - in endometrial tumors, 46:41
 - in esophageal cancer, 45:101
 - in melanoma, 44:61
 - in myomas, 44:1
 - in ovarian cancer, 45:223
 - in thyroid tumors, 44:119
 - in uterine tumors, 46:41
 - 1p in large bowel cancer, 44:107
 - 1q in pontine astrocytoma, 47:101
 - 2 del(2)(p23) in M2, 46:185
 - in cold agglutinin disease, 46:89
 - in mesothelioma, 46:135
 - in myomas, 44:1
- 3 in cervical cancer, 44:229
 - in esophageal cancer, 45:101
 - in lung tumors, 48:203
 - in ovarian cancer, 45:223
 - in renal cell carcinoma, 45:197
 - in uveal melanoma, 45:249
 - 3p in mesothelioma, 47:1
- 4 del(4) in CML, 44:55
 - in cervical cancer, 44:229
 - in large bowel cancer, 44:107
 - +4 in ANLL, 45:265; 47:265
 - +4 in biphenotypic acute leukemia, 47:265
 - 4 in mesothelioma, 47:1
- 5 del(5) in CML, 44:15
 - del(5) in MDS, 44:15; 46:157, 173
 - dic(5;11) in male breast cancer, 47:107
 - i(5p) in mesodermal tumor of ovary, 46:65
 - in cervical cancer, 44:229
 - in testis tumors, 48:1
 - +5 in mesothelioma, 47:1
 - 5q- in bladder cancer, 46:129
 - 5q in large bowel cancer, 44:107
- 6 in CLL, 45:143
 - in CMMoL (-7), 44:131
 - in lymphoma, 47:73
 - in melanoma, 44:61
 - in myomas, 44:1
 - in ovarian cancer, 45:223
 - in renal cell carcinoma, 45:197
 - in T-ALL, 44:69; 48:229
 - 6p in MDS, 44:271
- 7 in breast cancer, 46:217
 - in melanoma, 44:61
 - in myomas, 44:1; 47:179
 - in T-ALL, 44:69
 - in testis tumors, 48:1
 - +7 in bladder cancer, 50:9
 - +7 in mesothelioma, 47:1
 - +7, 7p and 7q in large bowel cancer, 44:83
 - 7/7q- in MDS, 44:15; 46:157; 48:67
- 8 i(8q) in large bowel cancer, 44:83
 - in lung tumors, 48:203
 - in pleomorphic adenomas, 46:55
 - in uveal melanoma, 45:249
 - +8 in ANLL, 45:67
 - +8 in MDS, 44:15; 46:157
 - 8q and 8p in large bowel cancer, 44:107
- 9 in esophageal cancer, 45:101
 - in renal cell carcinoma, 45:197
 - in T-ALL, 44:69
 - 9p in gliomas, 47:141
 - 9p in mesotheliomas, 47:1
 - 9p in ovarian cancer, 45:223

- 10 in endometrial cancer, 47:155
in large bowel cancer, 44:107
in myxoid chondrosarcoma, 45:207
10q22 in myoma and
leiomyosarcoma, 47:89
- 11 in cervical cancer, 44:229
in CLL, 45:143
in esophageal cancer, 45:101
in T-ALL, 44:69
in thyroid tumors, 44:119
+11 in large bowel cancer, 44:83,
107
11q23 in ANLL, 45:1
11q23 in AT, 46:1
11q23 in MDS, 45:73
- 12 i(12p) in CIS of testis, 46:75
i(12p) in ovarian tumor, 45:49
i(12q) in CLL, 50:171
in CLL, 45:143
in cold agglutinin disease, 46:89
in mesothelioma, 46:135
in myoma, 44:1; 47:179; 49:51
in T-ALL, 44:69
in testis tumors, 48:1; 50:67
+12 in myomas, 45:63
12p- in MDS, 44:15
12q13-14 in lipoma, 47:113
- 13 in CLL, 45:143
in large bowel cancer, 44:83, 107
in leukemia and preleukemia, 49:15
+13 in MDS, 48:179
13q14.11 in retinoblastoma, 48:265
- 14 in cervical cancer, 44:229
in CLL, 45:143
in large bowel cancer, 44:107
in myomas, 44:1; 47:179
in T-ALL, 44:69
inv(14) in AILD, 44:77
14q11.2 in T-cell lymphoma, 48:39
- 15 in large bowel cancer, 44:107
- 16 in large bowel cancer, 44:107
- 17 in breast cancer, 46:217
in cervical cancer, 44:229
in large bowel cancer, 44:83, 107;
46:143
in lung tumors, 48:203
in MDS, 44:15
in renal cell carcinoma, 45:197
17p in MDS and ANLL, 46:173
17p in medulloblastoma, 47:141
17p- in fibrosarcoma, 48:193
- 18 in breast cancer, 46:217
in large bowel cancer, 44:107;
46:143
iso(18q) in lymphoma, 44:279
- 19 +19 in MDS with thrombocytosis,
44:187
- 20 in breast cancer, 46:217
in large bowel cancer, 44:83
+20 in hepatoblastoma, 47:243
+20 in mesothelioma, 47:1
20q- in MDS, 46:157
- 21 in ANLL, 44:99
in breast cancer, 46:217
in large bowel cancer, 44:107
in M7, 48:119
pentasomy 1q in Down syndrome
with ANLL, 47:135
transient +21 in MPD, 48:259
21q22 in M4, 44:99
- 22 in meningioma, 45:273
in myxoid chondrosarcoma, 45:207
in M7, 48:119
in neurinomas, 45:55, 237
-22 in mesothelioma, 47:1
- X in large bowel cancer, 44:107
in myomas, 44:1
- Y in esophageal cancer, 45:269
-Y in MDS, 44:15; 46:157
-Y in meningiomas, 45:41
-Y in thorotrust exposure, 45:13
- Chronic lymphocytic leukemia (CLL)
B-cell type, 45:143; 50:171
chromosome changes, 45:143; 48:39;
183; 50:171
clinical implications of cytogenetic
changes, 45:143
i(12q) in, 50:171
molecular studies, 48:183
no +12 or t(11;14) by molecular studies,
48:183
normal karyotypes and molecular
studies, 48:183
T-cell type, 48:39
6, 11, 13 and 14 in, 45:143
+12 in, 45:143; 48:183
- Chronic myelocytic (myelogenous)
leukemia (CML)
bcr-abl changes, 44:143; 48:75; 209
blast crisis with -7 and dms, 48:133
BMT and chromosomes, 46:83; 47:55
chromosome changes in, 44:55, 181;
45:13; 46:83; 47:55, 197, 219; 48:75,
209; 49:15
chromosomes in cryopreserved cells,
45:179
complex rearrangements with 7
breakpoints, 48:75
i(17q) in (Ph-), 49:271
in child with bcr rearrangement, 44:277
in Hodgkin disease, 49:171
in radiation exposure, 45:13
juvenile type, 44:55
Klinefelter syndrome and, 48:135
masked Ph, 47:219
multiple clones in, 47:55
Ph chromosome, 44:181; 46:83; 47:197;
48:75, 209

- promyelocytic blast phase, 50:109
Robertsonian translocation, 45:193
t(15;17) in Ph+ CML in blast crisis, 50:109
translocations in, 46:83; 47:55, 197; 48:75
use of G-CSF, 47:277
variant Ph, 44:181; 46:83; 47:197, 219; 48:209
4 and 5 in, 44:55
Chronic myelomonocytic leukemia (CMMoL)
biclonal evolution, 44:131
chromosome changes in, 44:15, 131; 46:99, 157, 173
expression of FRA16B, 49:229
heterochromatin involvement, 46:99
in a child, 44:131
multiple clones, 47:171
prognostic and survival aspects, 44:15; 46:157, 173; 50:227
secondary (therapy-related), 46:173; 50:227
t(3;21) in, 50:227
unrelated clones, 47:171
Cold agglutinin disease
B-cell and, 46:89
chromosomes, 46:89
+3 and +12 in, 46:89
Colorectal tumors; see **Large bowel**
Culture
brain tumors, 47:141
establishment of cell line (ALL), 46:201
of MDS cells, 46:157
of prostatic cancer cells, 46:191
Culture media
conditioned, 46:107
factors of conditioned medium, 46:107
masking of chromosome changes in leukemia and, 46:107
Cytogenetics
in ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
in AML, 44:169; 47:139; 50:103
in ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107; 47:139, 171, 249; 48:119; 49:115, 277, 50:103, 161
in APL, 47:41; 50:109
in Askin tumor, 47:89
in bladder cancer, 49:143; 50:9
in brain tumors, 47:141
in breast cancer, 46:217; 47:107; 49:203
in cervical cancers, 44:229
in CIS of testis, 46:75
in cold agglutinin disease, 46:89
in colon polyps, 49:249
in dermatofibrosarcoma, 49:194, 273
in endometrial tumors, 46:41; 50:189
in erythroleukemia, 50:89
in esophageal cancer, 45:269
in esophageal cancer (cell lines), 45:101
in Ewing sarcoma, 47:61, 89
in fibrosarcoma, 48:193; 49:199, 273
in germ cell tumors, 50:67
in Hodgkin disease, 50:1
in kidney tumors, 45:197
in lipoma, 45:81; 47:113, 49:235
in liver tumor, 47:243
in lung tumors, 48:203; 49:37, 95, 185
in lymphoma, 44:279; 45:125, 231; 46:107; 47:73; 48:39; 49:219; 50:53
in meningiomas, 45:41, 237, 273
in mesothelioma, 46:135; 47:1
in M2, 46:185
in M3, 45:193
in M4, 44:99; 45:261
in M5, 46:99
in M7, 48:119
in neurinomas, 45:55
in osteosarcoma, 45:121; 50:125
in ovarian tumors, 44:223; 45:223; 46:65, 71, 115; 48:53, 243; 49:95, 50:67, 189
in Philadelphia-positive acute leukemia, 44:143; 47:29
in progeny of mother treated for AML, 50:169
in prostate cancer, 48:83
in radiation exposure, 45:13
in radiation-induced sarcomas, 50:125
in renal cell carcinoma, 45:197
in salivary gland tumors, 44:153; 46:35, 55; 50:161
in secondary leukemia, 44:275; 45:1; 46:173; 48:67, 125; 49:57, 171; 50:165
in secondary MDS, 46:173
in squamous cell carcinoma, 44:209; 47:131
in teratoma, 46:115
in testis, 46:75; 48:1, 143; 50:67
in uterine tumors, 46:41; 59:189
in uveal melanoma, 45:249
in Warthin's tumor (adenolymphoma), 46:35
in Wilms tumor, 45:35
multiple clones in ANLL and MDS, 47:171
of acute leukemia, Ph+, 44:143
of AILD, 44:77; 50:115
of CLL, 45:143; 50:171
of CML, 44:55, 143, 181; 45:13, 193; 46:83; 107; 47:55, 197; 48:75, 209; 49:15
of CMMoL, 44:15, 131; 46:99, 157, 173
of large bowel cancers, 44:83, 107; 46:143
of MDS, 44:15, 187, 271; 45:73, 193;

- 46:107, 125, 157, 173, 243; 47:171, 275; 49:113
 of melanoma, 44:61; 48:237
 of preleukemia, 49:15
 of refractory anemias, 44:15; 46:157, 173
 of T-ALL, 44:47, 69; 48:229; 49:1, 69; 50:31
 of thyroid tumors, 44:119, 217; 47:227
 of tuberous sclerosis, 45:161
 of uterine myomas, 44:1; 45:63; 47:89, 179; 49:51
 of uterine sarcomas, 44:27; 47:89; 48:217
 unrelated clones in ANLL and MDS, 47:171
- Deletions**
 del(2)(p23) in M2, 46:185
 in AILD, 50:15
 in ANLL, 45:1, 46:173
 in breast cancer, 46:217; 49:203
 in cervical cancers (1p-,3p-), 44:229
 in CLL, 45:143
 in CMMoL, 44:131
 in Hodgkin disease, 50:1
 in hydroxyurea-treated cases of MPD, 49:57
 in large bowel cancers, 44:83, 107; 46:143
 in leiomyosarcoma, 47:89
 in lung cancer, 49:37
 in lung tumors, 48:203; 49:37
 in lymphoma, 45:125; 49:265; 50:1, 53
 in MDS, 44:15; 47:275
 in melanoma, 44:61
 in mesothelioma, 47:1
 in myomas, 44:1; 47:89
 in ovarian tumors, 48:53, 243
 in salivary gland tumors, 44:153; 46:55; 50:161
 in squamous cell carcinoma, 44:209
 3p- in renal adenoma, 49:125
 4p- in renal cell carcinoma, 49:125
 4q- in CML, 44:55
 5q- in CML, 44:55
 5q- in MDS, 44:15; 46:157, 173; 47:171, 275; 48:67
 6q in lymphoma, 47:73
 6q- in T-ALL, 44:69; 48:229
 7q- in MDS, 44:15; 46:157, 173
 7q- in M4, 45:261
 9p- in gliomas, 47:141
 9p- in T-ALL, 44:69
 11q- in thyroid tumor, 44:119; 47:227
 12p- in MDS, 44:15; 47:275
 12p- in T-ALL, 44:69
 13q in leukemia and preleukemia, 49:15
 13q14.11 in retinoblastoma, 48:265
 17p- in fibrosarcoma, 48:193
 20q- in MDS, 46:157
 Xq25 in XLP, 47:163
Derivative chromosomes
 in breast cancer, 49:203
 in CIS of testis, 46:75
 in CMMoL, 44:131
 in Hodgkin disease, 50:1
 in Krukenberg tumor, 46:71
 in large bowel cancer, 44:83, 107; 46:143
 in lymphoma, 45:125; 47:73; 50:1
 in MDS, 45:73; 46:157, 173
 in mesothelioma, 47:1
 in salivary gland tumors, 46:55
 in thyroid cancer, 47:227
Dermatofibrosarcoma protuberans
 cytogenetics of, 49:199, 273
 in old burn scar, 49:199
 ring chromosome in, 49:273
 +8 and +8,+r in, 49:199
Dermoid cysts; see Teratoma
Desmoid cyst
 chromosomes in, 44:223
 DNA levels in, 44:223
 ovarian, 44:223
Dicentric chromosome
 dic(5;11) in male breast cancer, 47:107
 in medullary thyroid cancer, 47:227
DNA levels
 DNA content and karyotypes in thyroid tumors, 50:249
 in ovarian tumors, 44:223
 in testicular tumors, 48:143
 with flow cytometry, 44:223
DNA rearrangements
 in acute leukemia, 50:199
 in AT at 11q23, 46:1
 in bladder tumors, 49:143
 in brain tumors, 47:141
 in CLL, 48:183
 in CML, 44:143, 277; 47:219; 48:75; 49:15
 in large bowel cancer, 44:107
 in leukemia and preleukemia, 49:15
 in lymphoma, 49:219
 in MDS, 45:73; 46:243
 in neurinomas, 45:55
 in ovarian teratomas, 46:115
 in Ph+ acute leukemia, 44:143; 47:29
 in Ph+ ALL, 47:29
 in salivary gland tumors, 44:153; 48:209
 in T-ALL, 44:47; 48:229; 49:69
 in TCRA, 44:47; 46:281
 in testis tumors, 48:1
 of Y in meningiomas, 45:41
 masked Ph, 47:219
Double minute chromosomes (DMS)
 in blast crisis (lymphoid) of Ph+ CML, 48:133

- in brain tumors, 47:141
in erythroleukemia, 50:89
in hepatoblastoma, 47:243
in Krukenberg tumor cell line, 46:71
in leukocytes of girl with breast cancer, 44:203
in murine transformed cells, 49:75
no telomere sequences in, 48:271
- Down syndrome**
ANLL in, 47:135
Ewing sarcoma with t(11;22) in, 47:61
neonatal acute leukemia, 47:135
pentasomy of #21, 47:135
skeletal Ewing sarcoma in, 47:61
- Electron Microscopy**
and hereditary retinoblastoma, 48:265
detection of deletion at 13q14.11, 48:265
- Endometrial tumors**; see also *Uterus*
cell hybridization, 49:117
cell lines, 49:117
chromosome 10, 47:155
chromosomes in, 46:41; 47:155; 50:189
malignancies, 46:41; 50:189
malignant mixed müllerian tumor, 46:41
resistance to 6-thioguanine and G-418, 49:117
1q in, 46:41
- Ependymoma**
cytogenetics of, 47:141
- Epidermal growth factor receptor (EGFR)**
expression, 46:261
in melanoma cell line, 46:261
retinoic acid effects, 46:261
- Epiglottis**
cytogenetics of, 49:95
numerical chromosome changes, 49:95
squamous cell carcinoma, 49:95
- Erythroleukemia**; see *Acute erythroleukemia*
- Esophageal cancer**
cell lines, 45:101
cytogenetic studies, 45:101; 45:269
epidermoid carcinoma, 45:269
HSR in cell lines, 45:101
1, 3, 9 and 11 in cell lines, 45:101
+ Y and fra(X)(q28) in cancer, 45:269
- Ewing sarcoma**
chromosomes in, 47:61
in Down syndrome, 47:61
primary skeletal, 47:61
t(11;22) in, 47:61
- FAB classification**
chromosomes in M1, 47:139
chromosomes in M2, 44:169; 46:185
chromosomes in M3, 47:41
chromosomes in M4, 44:99; 45:1, 67
chromosomes in M5, 45:13; 46:99
- chromosomes in M7, 48:119
in MDS and chromosomes, 44:15; 46:157, 173
MDS vs M6, 49:139
- Familial tumors and diseases**
ataxia-telangiectasia, 50:119
neurofibromatosis, 45:245
sarcomas in neurofibromatosis, 45:245
T-cell leukemia, 49:157
X-linked lymphoproliferative disease (XLP), 47:163
- Fibroblasts**
cell line, SV40-transformed and karyotype evolution, 50:231
chromosomes in, 45:161
from café-au-lait spot of NF, 47:191
from normal skin of NF, 47:191
in tuberous sclerosis, 45:161
radiosensitivity in NF-6, 47:191
tetraploidy (in vitro) in colorectal cancer, 50:139
- Fibrosarcoma**
chromosome changes, 48:193
congenital, 48:193
17p-, 48:193
- Fish(es)**
erbB-like DNA, 50:45
genus *Xiphophorus* and linkage group VI, 50:45
- Fragile sites**
aphidicolin and, 50:35
Chinese hamster cell lines, 46:209
chromosomal, 44:37
expression of FRA16B, 49:229
folate-sensitive, 46:209
fragile(X)(q28) in esophageal cancer, 45:269
FRA16D at Xq27.2, 49:137
FRA16B in lymphocytes and marrow, 49:229
guide to, 44:37
in melanoma cells, 44:61
in neuroblastoma, 50:35
in parents of neuroblastoma cases, 50:35
SCE at Xq27.3 fragile site, 49:87
- Gains**
in brain tumors, 47:141
in large bowel cancer, 46:143
in mesothelioma, 47:1
in testis tumors, 48:143
in thyroid cancer, 47:227
of chromosomes in large bowel cancer, 44:107
- Germ cell tumors**; see also *Ovary and Testis*
in pineal region without i(12p), 50:153
- Glioblastoma**
cytogenetics of, 47:141

- giant cell, 47:141
- molecular studies, 47:141
- multiform, 47:141
- Gliosarcoma**
 - chromosomes in, 47:141
- Growth factors**
 - effect on MDS cells, 48:169
 - hematopoietic growth factors, 48:169
 - recombinant, 48:169
- Head and Neck**
 - chromosomes in SCC, 47:131; 49:95
 - epiglottis cancer, 49:95
 - squamous cell carcinoma (SCC), 47:131
- Hepatoblastoma**; see Liver
- Hepatocellular carcinoma**; see Liver
- Heterochromatin**
 - involvement in monocytic leukemia, 46:99
 - 1h, 4h and 9h in monocytic leukemia, 46:99
- Hodgkin disease (HD)**
 - chromosome changes, 50:1
 - Ph+ CML in treated HD, 49:171
 - serial studies, 50:1
- Homogeneously staining regions (HSR)**
 - in breast cancer, 49:203
 - in esophageal cancer cell lines, 45:101
 - in murine-transformed cells, 49:75
- HTLV-I carriers**
 - chromosomes in lymphocytes, 49:157
 - family study, 49:157
- Human Gene Mapping 10 (1989)**
 - book review, 49:141
- Hybrid leukemia**
 - t(8;21) in, 49:177
- Inversion**
 - in breast cancer, 46:217
 - in large bowel cancer, 46:143
 - in mesothelioma, 47:1
 - in salivary gland tumors, 46:55
 - inv(14) in angioimmunoblastic lymphadenopathy, 44:77
- Isochromosomes**
 - double i(18q) in lymphoma, 44:279
 - i(5p) in mesodermal tumor of ovary, 46:65
 - i(6p) and i(6q) in melanoma, 44:61
 - i(6p) in lymphoma, 47:73
 - i(7q) in melanoma, 44:61
 - i(8q) in lung tumors, 48:203
 - i(8q) in uveal melanoma, 45:249
 - i(11q) in M5a, 48:61
 - i(12p) in CIS of testis, 46:75
 - i(12p) in malignant ovarian tumor (yolk sac), 45:49
 - i(12p) in testis tumors, 48:1, 143
 - i(12q) in CLL, 50:171
 - i(17q) in CML (Ph-), 49:271
 - i(18q) in lymphoma, 44:279
 - in breast cancer, 49:203
 - in cervical cancers, 44:229
 - in large bowel cancer, 44:83, 107; 46:143
 - in MDS, 46:157
 - in mesothelioma, 47:1
 - pseudodicentric isochromosome 22 in meningioma, 45:273
 - 14q in MDS, 49:113
- Karyotypes**
 - in APL, 47:41; 50:109
 - in Askin tumor, 47:89
 - in brain tumors, 47:141
 - in CMMoL, 44:15, 131; 46:99, 157, 173
 - in Ewing sarcoma, 47:61, 89
 - in hydroxyurea-treated cases, 49:57
 - in liver tumor, 47:243
 - in MDS, 44:15, 187, 271; 45:73, 193; 46:107, 125, 157; 173, 243; 47:171, 275; 49:113
 - in melanoma, 44:61; 48:237
 - in progeny of mother treated for AML, 50:169
 - in prostate cancer, 48:83
 - in testis, 46:75, 48:1, 143, 50:67
 - in uterine myomas, 44:1; 45:63; 47:89, 179, 49:51
 - multiple clones in MDS and ANLL, 47:171
 - of acute leukemia, Ph+, 44:143
 - of AILD, 44:77; 50:15
 - of ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
 - of AML, 44:169; 47:139; 50:103
 - of ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107; 47:139, 171, 249; 48:119; 49:115, 277; 50:103
 - of bladder cancers, 49:143; 50:9
 - of breast cancer, 46:217; 47:107; 49:203
 - of cervical cancers, 44:229
 - of CIS of testis, 46:75
 - of CLL, 45:143; 50:171
 - of CML, 44:55, 143, 181; 45:13, 193; 46:83, 107; 47:55, 197; 48:75, 209; 49:15
 - of cold agglutinin disease, 46:89
 - of colon polyps, 49:249
 - of dermatofibrosarcoma, 49:199, 273
 - of endometrial tumors, 46:41; 50:189
 - of erythroleukemia, 50:89
 - of esophageal cancer, 45:101, 269
 - of fibrosarcoma, 48:193; 49:199, 273
 - of germ cell tumors, 50:67
 - of Hodgkin disease, 50:1

- of kidney tumors, 45:197
of large bowel cancer, 44:83, 107; 46:143
of lipoma, 45:81; 47:113; 49:235
of lung tumors, 48:203; 49:37, 95, 185
of lymphoma, 44:279; 45:125, 231;
 46:107; 47:73; 48:39; 49:219; 50:53
of meningiomas, 45:41, 237, 273
of mesothelioma, 46:135; 47:1
of M2, 46:185
of M3, 45:193
of M4, 44:99; 45:261; 50:103
of M5, 46:99
of M7, 48:119
of neurinomas, 45:55
of osteosarcoma, 45:121; 50:125
of ovarian tumors, 44:223; 45:223; 46:65,
 71, 115; 48:53, 243; 49:95; 50:67, 189
of Philadelphia-positive acute leukemia,
 44:143; 47:29
of radiation exposure, 45:13
of radiation-induced sarcomas, 50:125
of refractory anemias, 44:15; 46:157, 173
of renal cell carcinoma, 45:197
of salivary gland tumors, 44:153; 46:35,
 55; 50:161
of secondary leukemia, 44:275; 45:1;
 46:173; 48:67, 125; 49:57, 171
of secondary MDS, 46:173
of squamous cell carcinoma, 44:209;
 47:131
of T-ALL, 44:47, 69; 45:67, 137; 48:229;
 49:1, 69; 50:31
of teratoma, 46:115
of thyroid tumors, 44:119, 217; 47:227;
 50:249
of tuberous sclerosis, 45:161
of uterine sarcomas, 44:27; 47:89; 48:217
of uterine tumors, 46:41; 50:189
of uveal melanoma, 45:249
of Warthin's tumor (adenolymphoma),
 46:35
of Wilms tumor, 45:35
unrelated clones in MDS and ANLL,
 47:171
Kidney tumors
and von Hippel-Lindau disease, 49:125
bilateral renal carcinomas, 49:125
chromosome changes, 45:197; 49:125
del(3) in adenoma, 49:125
del(4) in renal cell carcinoma, 49:125
in Wiedemann-Beckwith syndrome,
 45:35
lymphangioma with 45,X,-X,i dic(7q),
 46:29
renal cell carcinoma, cytogenetics,
 45:197; 49:125
significance of +7 and loss of sex
 chromosomes, 49:259
Wilms tumor, 45:35
3, 7, 9 and 17 in renal cell cancer, 45:197
+7 and sex chromosome loss, 49:259
Klinefelter syndrome
 CML (Ph+), 48:135
Krukenberg tumor
 chromosomes in, 46:71
 of ovary, 46:71
Large bowel
 chromosomes and lymphocytes of
 polyposis cases, 47:69
 chromosomes in colorectal tumors,
 44:83; 44:107; 46:143; 49:249; 50:139
 cytogenetics of polyps, 49:249
 i(7p) and der(17) as only changes in two
 cancers, respectively, 44:83, 107
 i(8q) in rectosigmoid tumor, 44:83, 107
 molecular and cytogenetic data, 46:143
 polyploidization in cancer, 44:107;
 50:139
 polyposis cases in Norway, 47:69
 tetraploidy (in vitro) in sporadic cancer,
 50:139
 7, 17, 8, 11, 13 and 20 in large bowel
 cancer, 44:83, 107; 46:143
 +7 and +13 in polyps, 49:249
 +11 in colorectal cancer, 44:83, 107
 20p- and dup(20q) in colorectal cancers,
 44:83, 107
Larynx
 chromosome changes in cancer, 44:209
 squamous cell carcinoma, 44:209
Leiomyomas
 chromosomes in, 44:1; 45:63; 47:89, 179;
 49:51
 uterine, 44:1; 45:63; 47:89, 179; 49:51
 7, 12 and 14, 47:179
 10q22 in, 47:89
 12q14 in, 49:51
Leiomyosarcoma
 chromosomes in, 44:27; 47:89; 48:217
 subcutaneous, 48:217
 uterine, 44:27; 47:89; 48:217
 10q22 in, 47:89
 12q13 and 14q24 in, 48:217
Leukemia cells
 chromosomes in preserved cells, 45:179
 cryopreserved, 45:179
Lipoma
 chromosome changes, 45:81; 47:113;
 48:281
 complex chromosome anomalies, 47:113
 t(1;6) in, 48:281
 t(2;6)(q36;p21.3) in, 45:81
 t(X;12) in, 49:235
 6p in, 48:281
 12q13-14 in, 47:113

- Liposarcoma**
 t(12;16) in, 48:101
 12q13.3 and 16p11.2, 48:101
- Liver**
 chromosome changes in cancer, 45:255;
 47:243
 hepatoblastoma, 47:243
 hepatocellular carcinoma, 45:255
 +10 and dms in hepatoblastoma, 47:243
- Loss of heterozygosity (LOH)**
 in bladder cancers, 49:143
 in breast cancer, 49:215 (Table)
 in large bowel cancer, 46:143
 in leukemia and preleukemia, 49:15
 in MDS, 46:243
 in neurinomas, 45:55
 in testis tumor, 48:1
- Lung cancer**
 adenocarcinoma, 49:95, 185
 cell lines, 49:185
 chromosome changes, 48:203; 49:37, 95,
 185
 i(8q) in, 48:203
 numerical changes, 49:95
 squamous cell carcinomas, 49:37, 185
 3p and 17p, 48:203
 3p- in, 49:37
- Lymphangioma**
 of kidney, 46:29
 45,X,-X,i dic(7q) in, 46:29
- Lymphocytes**
 acrocentric interconnections, 50:207
 NOR variants, 50:207
- Lymphoma**
 chromosome changes in, 45:125; 47:73;
 48:39, 109, 199; 49:219; 50:53
 chromosome 6 in NHL, 47:73
 cold agglutinin disease and, 46:89
 del(7)(p13p14), 50:53
 deletions in, 49:265; 50:53
 double i(18q) in, 44:279
 effects of BCGF, 48:109
 follicular; small cleaved cell, 48:199
 histologic subtypes, 47:73
 Hodgkin disease, 50:1
 i(18q) in, 44:279
 in AT, 46:9
 molecular studies, 49:219
 Sézary syndrome, 44:193; 45:231; 46:281
 t(8;9)(q12;p21), 45:125
 t(14;18) and t(8;11) in follicular, 48:199
 t(14;19) in B-cell, 49:219
 T-cell, peripheral, 48:39
- Makino, Sajiro**
 obituary, 44:139
- Malignant fibrous histiocytoma (MFH)**
 chromosomes in, 50:125, 189
 secondary (radiation-induced), 50:25
- Mammary tumors; see Breast**
- Mastocytosis**
 chromosome changes, 48:13
 in bone marrow, 48:13
 malignant, 48:13
- Medulloblastoma**
 cytogenetics of, 47:141
- Melanoma**
 cell lines, 46:261; 48:237
 chromosome changes in, 44:61; 48:237
 EGFR expression in cell line, 46:261
 fragile sites in, 44:61
 malignant, 44:61; 48:237
 significance of chromosome changes
 48:237
 uveal, 45:249
 1, 6 and 7 in, 44:61
 -3 and i(8q) in uveal, 45:249
- Meningioma**
 chromosomes in, 45:41, 237; 47:141
 corrected figure psu iso(22) in 45:273;
 48:284
 histopathologic and chromosomal
 correlations, 45:237
 molecular studies (-Y) in, 45:41
 pseudodicentric isochromosome 22,
 45:273
 -Y in, 45:41
- Mesodermal tumor**
 chromosomes in, 44:27
 malignant of ovary, 46:65
 mixed, 44:27, 46:65
- Mesothelioma**
 asbestos exposure, 47:1
 chromosomes in, 46:135; 47:1
 peritoneal, 46:135
 pleural and pericardial, 47:1
 3 and 12p in, 46:135
 -4, -22, 9p- and 3p-, 47:1
 +5, +7 and +20, 47:1
- MIC IV (Conference on the Morphologic,
 Immunologic, and Cytogenetic
 Classification of Chronic (Mature) B
 and T Lymphoid Leukemias**
 report, 48:131
- Micronuclei**
 cancer risk and, 48:85
 in lymphocytes, 45:85
- Molecular studies**
 EGFR in melanoma cell line, 46:261
 in acute leukemia with t(11;19), 50:199
 in ALL, 49:15; 46:69
 in AML, 49:15
 in AT, 46:1
 in bladder cancer, 49:143
 in brain tumors, 47:141
 in breast cancer line, 46:271
 in chondrosarcoma (myxoid), 45:207
 in CLL, 48:183

- in CML, 44:143, 277; 47:219; 48:75, 209; 49:15
in hybrid leukemia with t(8;21), 49:177
in large bowel cancer, 44:107
in lymphoma, 49:219
in MDS, 45:73; 46:243
in melanoma cell line, 46:261
in meningiomas (-Y), 45:41
in Ph+ acute leukemia, 44:143; 47:29
in Ph+ ALL, 47:29
in preleukemia, 49:15
in salivary gland tumors, 44:153
in T-ALL, 44:47; 48:229; 49:69
in teratoma of the ovary, 46:115
in testis tumors, 48:1
masked Ph, 47:219
of erbB-like DNA in fishes, 50:45
of T-cell receptor, 44:47; 46:281
PCR in somatic cell hybrids, 45:217
RFLP studies in chondrosarcoma, 45:207
RFLP studies in neurinomas, 45:55
RFLP studies in teratomas, 46:115
X-chromosomes, 46:271
11q23 in AT, 46:1
- Monosomy
in AILD, 44:77; 50:15
in breast cancer, 46:217; 47:107
in cervical cancers, 44:229
in CIS of testis, 46:75
in Hodgkin disease, 50:1
in large bowel cancer, 48:83, 107; 46:143
in lung tumors, 48:203
in lymphoma, 45:125; 47:73
in MDS, 46:173
in mesothelioma, 47:1
in renal cell carcinoma, 45:197
in T-ALL, 44:69; 48:229
-3 in uveal melanoma, 45:249
-5 in CMMoL, 44:131; 46:157
-5 in MDS, 45:157; 48:67
-5, -7 in secondary leukemia, 48:67
-7 in blast crisis (lymphoid), 48:133
-7 in CML, 47:197
-7 in CMMoL, 44:131; 46:157
-7 in male breast cancer, 47:107
-7 in MDS, 44:15; 46:125, 157; 48:67
-7 in MPD, 49:57
-7 syndrome in children, 44:263
-10, -22, -X, -Y in gliomas, 47:141
-22 in meningioma, 45:237
-22 in neurinomas, 45:55
- Monosomy 7 (-7) syndrome
clinical heterogeneity, 44:263
in children and adolescents, 44:263
- Mouse
“dic” in Ehrlich-Lettré tumor, 48:23
- dms and HSR in transformed cells, 49:75
plasmacytoma, 46:93
variant (15;16) in plasmacytoma, 46:93
- Multiple myeloma
acute leukemia, 48:67
secondary leukemia following melphalan therapy, 48:67
- Myelodysplastic syndromes (MDS)
chromosome changes in, 44:15, 187, 271; 45:73, 193; 46:125, 157, 173, 243; 47:171, 275; 48:49, 169, 279
chromosome 17 in, 44:15
CMMoL, 44:15, 131; 46:99, 157; 47:171
cyopreserved cells, 45:179
effects of hematopoietic growth factors, 48:169
ETS1 in, 45:73
FAB subgroups, 44:15; 46:157, 173
leukemic transformation, 44:15
MDS vs M6, 49:139
molecular studies in, 46:243
morphology, course and prognosis, 44:15; 46:157, 173
multiple clones, 47:171
pseudo-Pelger-Huët, 46:173
RA, 44:15; 46:157, 173
RAEB, 44:15, 46:125, 157, 173
RAEB-t, 44:15; 46:157, 173; 47:171
RARS, 44:15; 46:157
secondary MDS, 46:173; 48:49, 67
sequential chromosome changes, 44:15
small vacuolated granulocytes, 46:173
spontaneous remission, 46:125
survival in, 44:19, 22; 46:173; 47:171
t(11;21) in, 46:243
therapy-related, 46:173; 48:49
thrombocytosis and +19, 44:187
translocation in, 46:173; 48:49
trisomy 8 (+8) in, 44:15; 47:171
unrelated clones, 47:171
use of G-CSF, 47:277
various cytogenetic techniques, 46:157
5q- in, 44:15; 47:171, 275; 48:49, 279
6p in MDS, 44:271
-7 and +8 in RAEB, 46:125
-7/7q- in, 44:15
11q23 and ETS1, 45:73
12p- in, 44:15; 47:275
+13 in MDS, 48:179
+19 and thrombocytosis, 44:187
-Y in, 44:15
- Myelofibrosis
and essential thrombocytosis, 45:193
chromosome changes, 49:57
hydroxyurea-treated cases, 49:57
Robertsonian translocation, 45:193
trisomy 14q in, 49:113
+14 in, 49:113

- Myeloma; see Multiple myeloma**
- Myeloproliferative disorders (MPD)**
- chromosomes in, 49:57
 - hydroxyurea-treated cases, 49:57
 - transient +21 in newborn, 48:259
 - +21 (transient), 48:259
- Myoma; see Leiomyoma**
- Nasopharyngeal cancer**
- cell line, 49:31
 - chromosomes in, 49:31
 - cytogenetic characterization, 49:31
- Neurinomas**
- chromosome changes in, 45:55
 - chromosome 22, 45:55
 - in neurofibromatosis, 45:55
 - in von Recklinghausen neurofibromatosis, 45:55
 - karyotypes in, 45:55
 - RFLP studies in, 45:55
- Neuroblastoma**
- aphidicolin and neuroblastoma (parents), 50:35
 - cell line, 45:131
 - fragile sites in patients, 50:35
 - marrow metastasis, 45:131
 - t(1;10)(p32;q24), 45:131
- Neurofibromatosis**
- fibroblasts from (radiosensitivity), 47:191
 - from skin and café-au-lait spot, 47:191
 - neurinomas in, 45:55; 47:141
 - peripheral nerve sheath tumors, 45:245; 47:141
 - radiosensitivity of fibroblasts from skin and café-au-lait spot, 47:191
 - rhabdomyosarcoma, embryonal, 45:245
 - sarcomas in three generations, 45:245
- Non-disjunction**
- aneuploidy, #21 and, 45:279
 - nature of, 45:277
- Non-Hodgkin lymphoma (NHL); see Lymphoma**
- Nucleolar organizing regions (NOR)**
- in lymphocytes, 50:207
 - variants in lymphocytes, 50:207
- Oligodendrogloma**
- chromosomes in, 47:141
- Oncogenes**
- abl* in Ph+ acute leukemia and CML, 44:143
 - c-mos* in pleomorphic adenomas of salivary gland, 49:165
 - c-myb* in T-ALL, 48:229
 - erbB*-like DNA in fishes, 50:45
 - EST1* in MDS with change at 11q23, 45:73; 46:243
- ets-1 transposition in acute leukemia**
- with t(11;19), 50:199
- H-ets-1 and H-ras in MDS**, 46:243
- in bladder cancer**, 49:143
- myc in brain tumors**, 47:141
- ras-p21 in salivary gland tumors**, 44:153
- 8q12 and c-mos**, 49:165
- Oral submucous fibrosis**
- SCE studies in patients, 44:197
- Osteosarcoma**
- chromosome changes, 45:121; 50:125
 - radiation-induced, 50:125
 - secondary, 50:125
 - small cell, 45:121
 - t(11;22) in, 45:121
- Ovary**
- adenocarcinomas 45:223; 48:53, 243; 49:95
 - Chinese hamster cell line, 46:231
 - chromosomes in malignant ovarian tumor, 44:223; 45:49, 223; 46:65, 71; 48:53, 243; 49:95; 50:189
 - clear cell tumor, 48:243
 - clonal evolution of cancer, 48:53
 - desmoid cyst, 44:223; 49:95
 - DNA studies in tumors, 44:223; 46:115
 - endometrioid carcinomas, 48:243
 - germ cell tumor cell line, 50:67
 - i(5p) in mesodermal tumor, 46:65
 - i(12p) in yolk sac tumor, 45:49
 - Krukenberg tumor, 46:71
 - mesodermal tumor (mixed, malignant), 46:65
 - metastatic tumor, 48:53
 - mucinous, 48:243
 - numerical changes in, 49:95
 - RFLP studies in teratomas, 46:115
 - sarcoma, 48:243
 - sclerosing stromal tumor, 49:103
 - squamous cell carcinoma, 48:243; 49:95
 - teratomas, 46:115
 - tumor of, 44:223; 45:49, 223; 46:71, 115; 48:53, 243; 49:95, 103; 50:189
 - yolk sac tumor, 44:223
 - 1, 3, 6 and 9 in, 45:223
 - 9p in cancer, 45:223
- Parathyroid tumors**
- adenoma, 48:225
 - t(1;5) in adenoma, 48:225
- Parotid gland**
- mucoepidermoid tumor, 50:161
 - t(3;8) and del(5q) as sole change in tumor, 50:161
- Peripheral nerve sheath tumors**
- in neurofibromatosis (familial), 45:245
- Philadelphia (Ph) chromosomes**
- disappearance in APL in relapse, 47:41

- in a child with Ph+ CML, 44:277
in acute leukemia, 44:143; 48:35
in ALL, 48:35; 49:1
in APL (M3), 47:41
in blastic phase, 47:219; 50:109
in CML, 44:143, 181; 46:83; 47:197; 48:75, 209; 50:109
late appearing in ALL, 48:35
masked, 47:219
molecular studies, 44:143, 277; 47:219; 48:75, 209
variant, 44:181; 46:83; 47:197, 219; 48:209; 50:109
- Pineal tumor
germ cell tumor without i(12p), 50:153
- Plasma cell leukemia (PCL)
chromosomes in, 47:47
ring chromosomes in, 47:47
- Plasmacytoma
chromosomes in, 46:93
mouse, 46:93
- Pleomorphic adenomas; see Salivary gland tumors
- Plexiform fibrohistiocytic tumor
cytogenetics, 48:31
- Polycythemia vera (PV)
ANLL in, 44:275
t(3;21) and AML in, 44:275
- Polymerase chain reaction (PCR)
chromosome mapping, 45:217
on somatic cell hybrids, 45:217
- Polyposis coli
chromosome changes, 49:249
high-resolution karyotypes in patients, 47:69
Norwegian cases, 47:69
tetraploidy in fibroblasts, 50:139
- Preleukemia; also see Myelodysplastic syndromes
chromosomes in, 49:15, 57
der(13) in, 49:15
molecular studies in, 49:15
retinoblastoma gene locus, 49:15
- Prematurely condensed chromosomes (PCC); see Prophasing
- Prophasing
acrocentric prophasing with BrdU, 50:269
in lymphocytes, 50:269
in patients with malignancy, 50:269
- Prostate
cytogenetic analysis, 46:191, 48:83
technique for culture of cancer cells, 46:191
+7, -9 in, 48:83
- Radiation exposure or therapy
chromosome abnormalities in, 45:13
effects of X-ray on Askin tumor, 47:89
effects on bone marrow, 45:13
effects on peripheral lymphocytes, 45:13
follow-up studies, 45:13
in Japan, 45:13
radiosensitivity of fibroblasts in NF, 47:191
radon-induced M4?, 48:125
relation to leukemia, 45:13
secondary (radiation-induced) sarcomas, 50:125
translocations and, 45:13
- Radon exposure
acute leukemia, 48:125
secondary M4 after 21 years, 48:125
- Rat
chromosome analysis of sarcoma, 50:75
Hirosaki sarcoma, 50:75
single cell transplantation, 50:75
- Receptors
EGFR in melanoma cell line, 46:261
TCR and t(7;14) in Sézary syndrome, 46:281
TCRA in T-ALL, 44:47; 49:69
- Rectosigmoid tumors; see Large bowel
- Refractory anemia (RA)
chromosome changes in, 44:15; 45:73; 46:157, 173; 48:67
ETS1 in, 45:73
i(14q) in, 49:113
prognostic and survival aspects, 44:15; 46:173
secondary (therapy-related), 46:173; 48:67
11q23 in, 45:73
- Refractory anemia with excess blasts (RAEB)
chromosomes in, 44:15; 45:73; 46:125, 157, 173; 48:67
ETS1 in, 45:73
multiple clones, 47:171
prognostic and survival aspects, 44:15; 46:125, 173
secondary (therapy-related) 46:173; 48:67
spontaneous remission, 46:125
thrombocytosis and +19, 44:187
unrelated clones, 47:171
-7 and +8 in, 46:125
11q23 in, 45:73
+13 in, 48:179
+14 in, 49:113
+19 in, 44:187
- Refractory anemia with excess blasts in transformation (RAEB-t)
chromosomes in, 44:15; 45:73; 46:157, 173
ETS1 in, 45:73

- multiple clones, 47:171
- prognostic and survival aspects, 44:15; 46:173
- secondary (therapy-related), 46:173
- unrelated clones, 47:171
- 11q23 in, 45:73
- Refractory anemia with ring sideroblasts (RARS)**
 - chromosome changes in, 44:15; 46:157
 - prognostic and survival aspects, 44:15
 - 6p in RARS, 44:271
- Renal tumors; see Kidney**
- Ring chromosomes**
 - in breast cancer, 49:203
 - in dermatofibrosarcoma, 49:199, 273
 - in medullary thyroid cancer, 47:227
 - in plasma cell leukemia, 47:47
- Retinoblastoma**
 - EM detection of deletion, 48:265
 - hereditary, 48:265
 - locus in leukemia and preleukemia, 49:15
 - subband deletion at 13q14.11, 48:265
 - 13q14.11 in, 48:265
- Rhabdomyosarcoma**
 - embryonal in neurofibromatosis, 45:245
- Robertsonian translocations**
 - in hematologic malignancy, 45:193
 - in leukemia, 45:193
 - in MDS, 45:193
- Salivary gland tumors**
 - adenolymphoma, 46:35
 - benign tumors, 44:153, 253; 46:35, 55
 - carcinoma arising in a pleomorphic adenoma, 44:253
 - cell line, 44:253; 46:55
 - chromosome changes in, 44:153, 253; 46:35, 55; 50:161
 - c-mos in adenomas, 49:165
 - malignant tumors, 44:153, 253
 - molecular studies in, 44:153
 - mucoepidermoid tumor of parotid, 50:161
 - pleomorphic adenomas, 46:55
 - t(3;8) and del(5q) as only changes, 50:161
 - tumors, 44:153, 253; 46:35, 55; 50:161
 - Warthin's tumor, 46:35
 - 8q12 and c-mos, 49:165
- Sarcoma**
 - chondrosarcoma, myxoid, 45:207
 - chromosomes in, 44:27; 49:199; 50:125
 - dermatofibrosarcoma, 49:199, 273
 - embryonal rhabdomyosarcoma, 45:245
 - Ewing sarcoma, skeletal, 47:61, 89
 - fibrosarcoma, 48:193; 49:199
 - Hirosaki sarcoma (rat), 50:75
- in neurofibromatosis (three generations), 45:245**
- leiomyosarcoma, 48:217**
- leiomyosarcoma of uterus, 47:89**
- osteosarcoma, 45:121; 47:89; 50:125**
- ovarian, 48:243**
- peripheral nerve sheath tumor, 45:245**
- radiation-induced, 50:125**
- secondary, 50:125**
- spindle cell, 50:125**
- synovial, 50:125**
- uterine, 44:27; 47:89**
- Secondary leukemia; also see ANLL**
 - chromosomes changes in, 44:275; 45:1; 46:173; 49:57; 50:165
 - following melphalan therapy, 48:67
 - following radon (21 years), 48:125
 - hydroxyurea-therapy of MPD, 49:57
 - in children, 45:1
 - in multiple myeloma, 48:67
 - M1, M2 and M6, 48:67
 - M4 and M5, 45:1
 - previous chemotherapy, 45:1; 46:173; 48:67
 - pseudo-Pelger-Huët in, 46:173
 - secondary APL (M3), 47:41
 - t(1;3) in M4, 50:165
 - t(3;21) in AML secondary to PV, 44:175
 - translocations in, 44:275; 45:1; 46:173; 47:41; 49:57
 - 11q23 anomalies in, 45:1
 - 17p in, 46:173
- Sézary syndrome**
 - chromosome studies in a patient, 44:193; 45:231; 46:281
 - cytogenetic follow-up, 45:231
 - lymphocytes and chromosomes, 44:193; 45:231
 - t(7;14) and TCR, 46:281
 - TCR in, 46:281
- Sister chromatid exchange (SCE)**
 - at Xq27.3 fragile site, 49:87
 - cancer risk, 45:85
 - in Bloom syndrome, 50:175
 - in lymphocytes, 45:85
 - in patients with oral submucous fibrosis, 44:197
 - no effect of EMS at Xq27.3, 49:87
 - synergistic effects of azathioprine and UV, 45:93
 - trans-acting factors and, 48:89
- Soft tissue tumors**
 - chromosome changes in, 50:125
 - fibrosarcoma, 48:193
 - leiomyoma, 44:1; 45:63; 47:95, 179
 - leiomyosarcoma, 48:217
 - lipoma, 45:81; 47:113
 - MFH, 50:125

- plexiform fibrohistiocytic tumor, 48:31
secondary, 50:125
spindle cell, 50:125
synovial sarcoma, 50:125, 277
- Sperm
chromosomes in, 46:251
effects of cancer treatment, 46:251
- Squamous cell carcinoma
chromosome changes in, 44:209; 47:131; 49:37
of head and neck, 47:131
of larynx, 44:209
of lung, 49:37, 185
ovarian, 48:243
translocations in, 47:131
- Synovial sarcoma
chromosomes in, 50:125, 277
endonuclease digestion studies, 50:277
secondary (radiation-induced), 50:125
 $t(X;18)$, 50:277
- T-cell
ALL (chromosome changes), 44:69; 45:137; 48:229; 49:1, 69, 241
ALL with $t(14;14)(q11.2;q32)$, 44:47
breakpoints in ALL with $t(14;14)$, 44:47
chromosome changes in peripheral T-cell lymphoma, 48:39
CLL, 48:39
family study of HTLV-I carriers; 49:157
HTLV-I carriers; cytogenetic study, 49:157
lymphocyte chromosomes in HTLV-I, 49:157
lymphoma, 48:39
receptor alpha chain, 44:47
Sézary syndrome, 44:193; 46:281
 $t(8;11)(q24;q11)$, 49:69
T-ALL cell line with $t(16;20)$; 49:241
6q- in ALL, 48:229
- Techniques
G-CSF in myeloid leukemias and MDS, 47:277
- Telomere
no sequences in dms, 48:271
- Teratoma
benign, 46:115
chromosomes in, 46:115
of ovary, 46:115
origin of, 46:115
RFLP zygosity, 46:115
- Testis
adult tumors, 48:143
autosomal dosage, 48:1
cell lines, 50:67
chromosome changes in, 46:75; 48:1, 143; 50:67
CIS of, 46:75
- cytogenetic model, 48:143
germ cell tumors, 48:143; 50:67
 $i(12p)$ in, 46:75; 48:1, 143; 50:67
molecular studies in tumors, 48:1
pathogenesis, 48:143
seminoma, 48:1, 143
teratocarcinoma, 48:1
tumor of, 46:75; 48:1, 143; 50:67
yolk sac tumor, 48:143
- Therapy-related ANLL and MDS; see Secondary leukemia
- Thorotrast
effects on chromosomes, 45:13
-Y, 45:13
- Thrombocytosis
+19 in MDS with, 44:187
- Thyroid
adenomas, follicular, 44:119, 217
chromosomes in tumors, 44:119, 127 (Table), 217; 47:227; 50:249
DNA content, karyotypes and clinical data, 50:249
follicular adenomas, 44:119, 217; 50:249
hypodiploid, pseudodiploid and normal karyotypes in medullary cancer, 47:227
medullary carcinoma, 47:227; 50:249
metastatic cancer, 47:227
oxyphil cell adenoma, 50:249
papillary cancers, 44:119; 50:249
1 and 11 in tumors, 44:119
- Transient changes
MPD with +21 (transient), 48:259
+21 in newborns, 48:259
- Translocations
in AILD, 50:15
in ALL, 44:143; 46:201; 49:1; 50:31
in AML, 44:169, 47:139
in ANLL, 44:99, 143, 169; 45:1, 67; 46:99, 173; 47:139; 48:255
in APL, 47:41
in Askin tumor, 47:89
in breast cancer, 46:217; 47:107
in cervical cancers, 44:229
in CIS of testis, 46:75
in CML, 46:83; 47:55, 197; 48:75, 209
in CMMoL, 46:99
in endometrial tumors, 46:41
in Ewing sarcoma, 47:61, 89
in Hodgkin disease, 50:1
in large bowel cancers, 44:83; 46:143
in leiomyosarcoma, 48:217
in lipoma, 45:81; 47:113
in lung tumors, 48:203
in lymphoma, 45:125; 47:73; 48:199
in MDS, 46:157, 173, 243
in meningioma, 45:237
in mesotheliomas, 47:1

- in myoma, 44:1; 49:51
 in M4, 44:99; 45:261; 48:255
 in M7, 48:119
 in osteosarcoma, 45:121
 in radiation exposure, 45:13
 in radiation-induced sarcomas, 50:125
 in salivary gland tumors, 44:153; 46:55
 in squamous cell carcinoma, 44:209;
 47:131
 in T-ALL, 44:69; 49:1; 50:31
 in tuberous sclerosis, 45:161
 in uterine tumors, 46:41
 in Wilms tumor (X;20), 45:35
 Philadelphia chromosome, 44:143, 181
 Robertsonian, 45:193
 $(?;5)(5;21)(?;q35p11;q11)$ in
 subcutaneous leiomyosarcoma of the
 knee, 48:217, 220
 $(?;14)(?;q12\rightarrow q22::q24\rightarrow qter)$ c-myb gene
 in T-cell malignancies, 48:233
 $(?;16)(?;q12.2)$ c-myb gene in T-cell
 malignancies, 48:232
 $(X;?)(p11;?)$ B cell growth factor (BCGF)
 and lymphoma cytogenetics, 48:111
 $(X;?)(p22;?)$ in NHL, 47:78
 $(X;?)(Xqter\rightarrow Xp22::?)$ in male breast
 cancer, 47:108
 $(X;1)(q22;p13)$ in a thyroid carcinoma,
 50:256
 $(X;1;13)(Xpter\rightarrow Xq23::1p36.2\rightarrow 1pter;1qter\rightarrow$
 1p31.3::13q33\rightarrow 13qter;13pter\rightarrow
 13q33::1p31.3\rightarrow 1p36.2::Xq23\rightarrow Xqter) in
 neurinoma, 45:57–58
 $(X;3)(p11;p21)$ in de novo MDS, 44:21
 $(X;6)(p22;q21)$ in benign uterine
 leiomyoma, 44:4
 $(X;7)(q11;q36)$ in NHL, 47:78
 $(X;9;11;22)(p11;q34;q12;q11)$ atypical
 Ph+ CML, 44:181, 182, 184–185
 $(X;9;22)(q11;q22;q12)$ atypical Ph+
 CML, 44:185
 $(X;9;22)(q27;q34;q12)$ atypical Ph+
 CML, 44:185
 $(X;10)(q13;p11-12)$ in adenolymphoma,
 46:37
 $(X;10)(q13;q26)$ in human malignant
 melanoma (HMM), 48:238–239
 $(X;10)(q22q23;q24)$ in an ependymoma,
 49:237
 $(X;11)$ in salivary gland pleomorphic
 adenoma (PSA), 46:60
 $(X;11)(q26;q21)$ in colorectal tumor,
 44:93
 $(X;11)(Xpter\rightarrow Xq26::11q23\rightarrow 11qter;11pter\rightarrow$
 ataxia-telangiectasia (A-T) gene locus,
 46:1–3, 5
 $(Xq11q)$ in breast cancer, 49:205
 $(X;12)(p22.3;q15)$ in uterine leiomyoma,
 49:54, 237
 $(X;12)(q27;q14)$ in a lipoma, 49:235–237
 $(X;14)$ mapped in T-cell ALL, 44:50, 51
 $(X;18)$ in soft tissue sarcoma, 50:126,
 132
 $(X;18)$ in synovial sarcoma, 50:277–278
 $(X;18)(p11;q11)$ in fibrosarcoma,
 48:196–197
 $(X;18)(p11.2;q11.2)$ in synovial sarcoma,
 49:237; 50:277–278
 $(X;19)(q22;q13.1)$ in thyroid adenoma,
 50:254
 $(X;20)(q11;q11)$ in a child with Wilms
 tumor associated with
 Wiedemann-Beckwith syndrome,
 45:35, 36–38
 $(X;22)(p22;q11)$ atypical Ph+ CML,
 44:185
 $(X;22)(q28;q11)$ atypical Ph+ CML,
 44:181, 182, 185
 $(Y;1)(q12;q21)$ in B-cell lymphoma,
 49:221–222
 $(Y;4)(q12;q21)$ in adenolymphoma,
 46:37
 $(Y;12)$ in salivary gland pleomorphic
 adenoma (PSA), 46:60
 $(Y;15)(q12;q14$ or $q15)$ in malignant
 mesothelioma (MM), 47:11, 14, 23
 $(1;?)$ in bladder carcinoma, 49:145
 $(1;?)$ in NHL with del(7)(p14), 50:55
 $(1p?)$ in esophageal carcinoma cell line,
 45:111
 $(1;?)(p32;?)$ in hepatocellular carcinoma,
 45:259
 $(1;?)(p34;?)$ in NHL, 47:78
 $(1;?)(p36;?)$ in malignant mixed
 mesodermal tumor of ovary, 46:65, 67
 $(1;?)(p36;?)$ in NHL, 47:78
 $(1;?)(q?11;?)$ B cell growth factor (BCGF)
 and lymphoma cytogenetics, 48:111
 $(1;?)(q21;?)$ in de novo MDS, 44:21
 $(1;?)(q25;?)$ in carcinoma of the cervix
 uteri, 44:230
 $(1;?)(q42;?)$ in MDS and ANLL, 46:178
 $(1;?)(q42;?)$ in NHL, 47:78
 $(1;?)(1qter\rightarrow 1q11::?)$ marker chromosome
 in a rare pineal region mixed germ
 tumor, 50:156–157
 $(1;1)$ in neuroblastoma, 45:134
 $(1;1)$ in thyroid tumor, 44:127
 $(1;1)(p32;q21)$ in neuroblastoma cell
 line, 45:131
 $(1;1)(p32;q25)$ in NHL, 47:78
 $(1;1)(p32;q32)$ in uterine
 leiomyosarcoma, 48:217, 220–221
 $(1;1;15)(q21;p12;p13)$ in SCC of the
 larynx, 44:211
 $(1;2)(p33;q24)$ in thyroid tumor, 44:127
 $(1;2)(p33;q34)$ in ANLL in relapse,
 44:174

- (1;2)(p36;p24) in benign uterine leiomyoma, 44:10; 47:97
(1;2)(q22;q33) in adenocarcinoma of the prostate, 48:86
(1;2)(q44;q31) from radiation-induced tumors, 50:128
(1;2;17)(p13;p12;q24) in esophageal carcinoma cell line, 45:105–106
(1;3) in MDS, 46:158
(1;3) in NHL with del(7)(p11p15), 50:55
(1;3)(p11;q11) in esophageal carcinoma cell line, 45:107
(1;3)(p12;q21) from radiation-induced tumors, 50:128
(1;3)(p32-p34;q27-q29) in angiofibroma, 45:168
(1;3)(p33;p21) RCC, 45:199
(1;3)(p33;q26) in T-cell ALL, 44:70
(1;3)(p36;q21) before and after BMT, 47:258
(1;3)(p36;q21) with –7 in M4 ANLL secondary to multiple myeloma, 50:165–167
(1;3)(q11;p11) in esophageal carcinoma cell line, 45:107
(1;3)(q21,q29) in endometrial adenocarcinoma, 46:42–45, 50
(1;3)(q23;q23) in lipoma, 47:116–117, 120, 127
(1;3)(q23 or q25;q29) in Ph+ CML BC, 47:198, 200, 211
(1;3)(q44;p12) in SCC of the larynx, 44:211, 213, 215
(1;3;2)(p32;p21;q37) in uterine sarcoma, 44:32, 33
(1;3;5;9;22) masked Ph in CML, 47:223
(1;3;6)(p36;q21;p21) in a lipoma, 45:83
(1;3;8)(p22;p21;q12) in pleomorphic adenoma (PSA), 49:166
(1;4) in breast cancer, 46:217
(1;4)(1pter→1p22::4p14→4qter) in male breast cancer, 47:108
(1;4)(p22;q28) in SCC of the larynx, 44:211, 212, 215
(1;4)(q21;q21) in human malignant melanoma (HMM), 48:240–241
(1;5) in a child with CML, 46:86–87
(1;5) in breast cancer, 46:217
(1;5)(p13;q12) in endometrial adenocarcinoma, 46:50
(1;5)(p14;q13) in de novo MDS, 44:21
(1;5)(p22;q32) in parathyroid adenoma, 48:225, 227–228
(1;5)(q21;p15) in PLL, 48:184
(1;5)(q21 or q22;q31) in Ph+ CML in CP, 47:204, 207, 211
(1;5)(q25;p15) in SCC of the larynx, 44:211, 213
(1;5)(q43;q12) in ANLL, 44:173
(1;6) in bladder carcinoma, 49:145
(1;6)(p12;p23) in ANLL, 45:67
(1;6)(p13;p21.3) in ANLL, 45:68–69
(1;6)(p13;p23) in ANLL evolving from MDS, 45:67, 69
(1;6)(q24;p22) in benign lipoma, 48:281–282
(1;6)(q32;p21) in uterine sarcoma, 44:32, 33
(1;6)(q42;p23) in adenolymphoma, 46:37
(1;7) in breast cancer, 49:206
(1;7) in exposure to cytotoxic substances in t-MDS, 46:170
(1;7) in t-MDS, 46:158, 170
(1;7)(p11;p11) in hematologic disorders, 45:67, 69; 48:51
(1;7)(p11;p11) in RA, 46:163
(1;7)(p31;q35) in breast cancer, 49:213
(1;7)(p32;p22) after radiation therapy in Askin's tumor, 47:90–92
(1;7)(p32;q34) in a thyroid carcinoma, 50:255–256
(1;7)(q12;p22) in radio- or chemotherapy treated sperm, 46:255
(1;7)(q21-q23;q32-q36) in angiofibroma, 45:168, 170
(1;7;14)(q25;q32;q22) in meningioma, 45:239
(1;8)(p11;q11) in childhood erythroleukemia, 49:28
(1;8)(p22;q12) in pleomorphic adenoma (PSA), 49:166
(1;8)(q32;q21) Ph+ cells in unstimulated PB, 47:261
(1;8)(q32;q21) Ph– cells in unstimulated PB after second BMT, 47:261
(1;9) in lipoma, 47:116, 121, 125
(1;9)(p11;p13) in RCC, 45:199
(1;9)(p11;q11) in nasopharyngeal carcinoma, 49:32–33
(1;9)(p13;p13) in breast cancer, 46:224
(1;9)(p22;q31) in human malignant melanoma (HMM), 48:240–241
(1;9)(p22;q34) in SCC of the larynx, 44:215
(1;9)(p31;q21) in angioimmunoblastic lymphadenopathy (AILD), 50:22
(1p9q) in breast cancer, 49:205–206, 208
(1;9)(q11;p21) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(1;9)(q12;13) in CMMoL, 46:99, 101–104
(1;9)(q23;p13) in childhood pre-B ALL, 46:201, 205–207
(1;9)(q23-25;p22-21) in ALL, 45:125, 128
(1;9)(q4?1;q13) in endometrial adenocarcinoma, 46:42–43, 45, 50
(1;9)(q43;q21) in mixed mesodermal tumor of ovary, 46:65, 67

- (1;10)(p12;q22.3) from radiation-induced tumors, 50:128
- (1;10)(p32;q24) in neuroblastoma cell line, 45:131, 133–134
- (1;11)(p12;q24) in diffuse large cell NHL, 50:54
- (1;11)(p21;p12) in esophageal carcinoma cell line, 45:103
- (1;11)(p21;q25) in uterine sarcoma, 44:32, 33
- (1;11)(p32;p15) in neuroblastoma cell line, 45:131
- (1;11)(p32;q23) in ALL, 49:3
- (1;11)(q21 or q23;p15) in Ph+ CML in BC, 47:200, 211
- (1;11;4)(q31;q13.1;p16) in Sézary syndrome, 44:194
- (1;11;12)(1pter→1q21::12q13→12qter;1qter→1q21::11p13→11qter;12pter→12q13::11p13→11pter) with congenital anomalies in progeny of a mother treated for childhood leukemia, 50:169–170
- (1;12) in lipoma, 47:127
- (1;12) in mixed and myxoid liposarcoma, 48:104
- (1;12)(p22;p13) in childhood erythroleukemia, 49:28
- (1;12)(12qter→12p11.2::1p13→1p34:) in male breast cancer, 47:108
- (1;12)(q21;q13) in salivary gland pleomorphic adenoma (PSA), 46:57
- (1;12)(q43;q14) in uterine leiomyoma, 49:53–54
- (1;13) in neuroblastoma, 45:134
- (1;13)(p36;q14) in MDS, 49:114–116
- (1;14)(p13;q11?) in angioimmunoblastic lymphadenopathy (AILD), 50:19, 22
- (1;14)(p32;q11) in T-cell ALL, 44:70, 72
- (1;14)(q23;q32) in T-cell ALL, 44:70
- (1;15) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
- (1;15) in endometrial adenocarcinoma, 46:45
- (1;15)(p36;q15) in benign uterine leiomyoma, 44:5
- (1;15)(p36.1;q11.2) from radiation-induced tumors, 50:128
- (1;15)(q12;p11) in RA, 46:160, 163, 166, 169
- (1;15)(q34;q21) in ALL, 46:111
- (1;16) in endometrial adenocarcinoma, 46:45
- (1;16) in Ewing sarcoma, 45:9
- (1;16)(p32;p12) in ANLL, 44:173
- (1;16)(q11;q11) in a thyroid adenoma, 50:256
- (1q16p) in breast cancer, 49:204, 206–207, 210–211, 213
- (1;17) in PCL, 47:52
- (1;17)(p12;p11) in RA, 44:23
- (1;17)(q31 or q32;p11) in Ph+ CML in CP, 47:202–204, 210
- (1;18)(p31;q23) in SCC of the larynx, 44:211–212
- (1;18)(p32;q12) in a thyroid adenoma, 50:256
- (1;18)(p32;q12.1) in a thyroid adenoma, 50:255
- (1;18)(p36;q22) in T-ALL, 50:31
- (1;18)(1p35→1p13::18p11.2→18qter) in male breast cancer, 47:108
- (1;19) in childhood ALL, 49:4
- (1;19) poor-risk subgroup in ALL, 49:8
- (1;19)(p21;p13) in de novo MDS, 44:21
- (1;19)(q23;p13) in childhood pre-B ALL, 46:201, 205–207
- (1;19)(q23;p13) in pre-B cell ALL, 44:69, 45:183–184
- (1;19)(q23;p13.3) in ALL, 49:3
- (1;19)(q31;qter) in breast cancer, 49:205
- (1q21q) in breast cancer, 49:206, 210, 213
- (1;22) in endometrial adenocarcinoma, 46:45, 51
- (1;22)(p32;q12) in breast cancer, 49:204, 206, 213
- (1;22)(q32;q13) in fibrosarcoma, 48:196
- (1q22q) in breast cancer, 49:213
- (1;22;9)(p32;q11;q34) masked Ph in CP and BP of CML, 47:219, 221–223
- (2;?) in thyroid tumor, 44:127
- (2;?)(p13;?) in Sézary syndrome, 45:235
- (2;?)(p21;?) in Hodgkin's disease (HD), 50:7
- (2;?)(p21;?) in NHL, 47:78
- (2;?)(p24;?) in NHL, 47:78
- (2;?)(p25;?) in mixed mesodermal tumor of ovary, 46:65, 67
- (2;?)(q37;?) in Hodgkin disease (HD), 50:3
- (2;2)(p15;q21) in esophageal carcinoma cell line, 45:106, 112
- (2;3) in NHL with del(7)(p11p15), 50:55
- (2;3)(p23;p21) in patients administered Thorotrast, 45:22–23
- (2;3)(q11;qter) in NHL, 47:78
- (2;3)(q12;p24) in a thyroid adenoma, 50:256
- (2;3)(q33;p21) in nasopharyngeal carcinoma, 49:32–33
- (2;4) in a SV40 virus-transformed tumorigenic human cell line, 50:231
- (2p4q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242–243, 245

- (2;4;19) DMS and +7 in BC of CML, 48:133-134
(2;5)(p23;p15) after radiation therapy in Askin's tumor, 47:90, 92
(2;5)(q21;q33) in SCC of the larynx, 44:211, 213, 215
(2;5)(q37;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(2;5;5;10;12) in lipoma, 47:115-117
(2;5;9)(p11;q13;p24) in SCC of the larynx, 44:211
(2;6)(p23;q21) in SCC of the head and neck, 47:131-133
(2;6)(q21;q21) in peripheral T-cell lymphoma (PTCL), 48:42
(2;6)(q36;p21.3) in a lipoma, 45:81-82
(2;6)(q36;q23) in NHL, 47:78
(2;7)(q21;p22) as a primary change in M5 ANLL, 49:278
(2;7;14)(q23;q36;q22) in meningioma, 45:239
(2;8) in Burkitt lymphoma, 46:93
(2;8) poor-risk subgroup in ALL, 49:8
(2;8)(p12;q24) IGK and MYC in B-ALL, 49:6
(2;8)(p12;q24) in B-ALL, 49:3
(2;8)(p12;q24) in Burkitt lymphoma, 49:72
(2;8)(p13;q24) from radiation-induced tumors, 50:128
(2;8)(q13 or q14;q24.1) in B-cell lymphoma, 49:219, 222
(2;9)(p12;q13) in a thyroid adenoma, 50:256
(2;9)(q13;q34) in SCC of the larynx, 44:215
(2;9;22)(p15 or p13;q34;q11) variant in CML, 47:199
(2;11)(p15;q13) from radiation-induced tumors, 50:128
(2;11)(p21;q23) in MDS, 45:73; 46:158; 163, 170
(2;11)(q21;q11) in human malignant melanoma (HMM), 48:240-241
(2;11;19)(q22;p13;q13.3) in a prostatic tumor, 48:221
(2;12)(p11.2;p13) in childhood erythroleukemia, 49:28
(2;12)(p12;q13) in Sézary syndrome, 45:235
(2;12)(q11;p13) normal karyotype in leukemic cells before BMT, 47:254
(2;12)(q21;q24) in adenolymphoma, 46:37
(2;12)(q37;q14) in uterine leiomyoma, 49:54
(2;13)(q23;q14) in radio- or chemotherapy treated sperm, 46:255
(2;13)(q37;q14) in rhabdomyoma, 44:33
(2;13;13)(p22q37;q11;q11) in Sézary syndrome, 45:235
(2;14) in a SV40 virus-transformed tumorigenic human cell line, 50:231
(2;14) in NHL with del(7)(p11p15), 50:55
(2p14q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 241-245
(2;14)(p13;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(2;14)(p13;q22) from radiation-induced tumors, 50:128
(2;14)(q23;q32.3) in M4 ANLL, 48:255-257
(2;15)(p11;p11-p13) in angioblastoma, 45:168, 171
(2;15)(p23 or p25;q15) in Ph+ CML in CP, 47:202-203, 210
(2;15)(p23;q26) in fibrosarcoma, 48:196
(2;15)(q11;q15) in Ph+ CML in CP, 47:202, 205
(2;15)(q31;q15) in childhood erythroleukemia, 49:28
(2;16)(p11.2;q24) in human malignant melanoma (HMM), 48:240-241
(2;17)(q21;q21) from radiation-induced tumors, 50:128
(2;18) in acute megakaryoblastic leukemia (ANLL-M7), 48:119
(2;18)(q13;q23) in human malignant melanoma (HMM), 48:240-241
(2;18)(q33;p11) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-121
(2;21)(p11;q11) in t-MDS progressed to "frank" leukemia, 48:50
(2;21)(p15;q22) normal karyotype in leukemic cells before BMT, 47:255
(2;22)(q13;q13) in esophageal carcinoma cell line, 45:103
(2;22)(q37;q11) variant in CML, 47:199
(3;?) in a SV40 virus-transformed tumorigenic human cell line, 50:231, 239, 244
(3;?) in bladder carcinoma, 49:145
(3;?)(p1?)(p1?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
(3;?)(p13;?) in MDS and ANLL, 46:178
(3;?)(p24;?) in NHL, 47:78
(3;?)(q21;?) in de novo MDS, 44:21
(3;?)(q26;?) normal karyotype in leukemic cells before BMT, 47:254
(3;?)(q27;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242-244

- (3;?)(q27 or 29;?) in Hodgkin's disease (HD), 50:7
 (3;?)(q29;?) in NHL, 47:78; 50:54
 (3;3) in MDS, 46:166
 (3;3) in megakaryoblastic crisis of CML, 47:57
 (3;3)(p25;q29) in erythroleukemia (EL), 50:91–92
 (3;3)(q21;q26) in RAEB-t, 46:160, 163
 (3;3)(q28 or 29;p12 or 13) in a SV40 virus-transformed tumorigenic human cell line, 50:243–244, 246
 (3;4)(p21 or p22;q12) in MDS, 45:75
 (3;4)(p21;q31) in malignant mesothelioma (MM) 47:11
 (3;4)(p21;q34) in malignant mesothelioma (MM) 47:27
 (3;4)(p25;p13) in angioimmunoblastic lymphadenopathy (AILD), 50:19
 (3;4)(q21;p12) alteration in RB1 gene in leukemia, 49:18
 (3;4)(q26;q21) growth factors (rhGM-CSF) in MDS, 48:169, 171, 174–175
 (3;4;8)(p26;p13 or p14;q12) in pleomorphic adenoma (PSA), 49:166
 (3;4;9;11;22) in CML, 46:87
 (3;4;9;22)(q27;q31;q22;q11) atypical Ph+ CML, 44:181, 182, 184
 (3;5)(p25;p15.3) from radiation-induced tumors, 50:128
 (3;5)(q23;q31) in bladder carcinoma, 49:109
 (3;5)(q25;q22) in L1 T-cell ALL, 45:137
 (3;6)(p13;q27) in acute megakaryoblastic leukemia (ANLL-M7), 48:119–122
 (3;6)(p14;q11) in esophageal carcinoma cell lines, 45:115
 (3;6;14)(q12;q23;p11) in SCC of the larynx, 44:211, 214
 (3;7) alteration in RB1 gene in leukemia, 49:18
 (3;7) in thyroid tumor, 44:127
 (3;8)(p12;q12) in mixed salivary gland tumor, 36:52
 (3;8)(p21;q12) in a mucoepidermoid tumor of the parotid gland with del(5)(q22), 50:161–163
 (3;8)(p21;q12) in pleomorphic adenoma (PSA), 49:166
 (3;8)(p21;q12) in salivary gland pleomorphic adenoma (PSA), 44:154, 155, 161; 46:55, 58, 60
 (3;8)(p21 or p23;q12 or q13) in salivary gland pleomorphic adenoma (PSA), 46:60
 (3;8)(p23;q12) in salivary gland pleomorphic adenoma (PSA), 46:60
 (3;8)(3qter→3p26::8q12→8qter) in pleomorphic adenoma (PSA), 49:166
 (3;9)(p11;p11) in childhood erythroleukemia, 49:27
 (3;9)(p11;p21) in childhood erythroleukemia, 49:28
 (3;9)(p25;q34) in SCC of the larynx, 44:215
 (3;9)(q13;p21) in AML, 46:111
 (3;9)(3qter→3q12::9q12→9pter) in male breast cancer, 47:108
 (3;9)(q23 or q25;p13 or p21) in salivary gland pleomorphic adenoma (PSA), 46:57
 (3;9)(q23;p22) in childhood erythroleukemia, 49:27–28
 (3;10)(q22;q22) in malignant mesothelioma (MM) 47:11, 22
 (3;10)(q26;q24) in NHL, 47:78
 (3;11)(q21-q23;p14) in ANLL in relapse, 44:173
 (3;11)(q25;q13) from radiation-induced tumors, 50:128
 (3;11)(3qter→3p12::11q13→11qter) in male breast cancer, 47:108
 (3;12)(p21;q23) in malignant mesothelioma (MM), 47:11, 24
 (3;12)(3pter→3p12::12p11.2→12qter) in male breast cancer, 47:108
 (3;12)(q13;p13) in peritoneal mesothelioma, 46:135–136
 (3;?12)(q25;?q21) in nasopharyngeal carcinoma, 49:32
 (3;12—(q26;p12) CMMoL in a child, 44:131–136
 (3;12)(q28;q14) in benign lipoma, 46:52; 47:127
 (3;13)(q12-q13;q33-q34) in angiofibroma, 45:168–169
 (3;13)(q13;q34) as a primary change in M5 ANLL, 49:277–278
 (3;14)(q13;q11) in angioimmunoblastic lymphadenopathy (AILD), 50:19
 (3;14)(q21;q32) in de novo MDS, 44:21
 (3;15)(q29;q12) in ANLL, 44:173
 (3;16)(p21;q24) in human malignant melanoma (HMM), 48:240–241
 (3;16)(q21;p13) in NHL, 47:78
 (3;17) in a child with bilateral nephroblastoma, 45:36
 (3;17)(p11;q11-q12 or q21.1) in MDS, 44:273
 (3;17)(p11;q25) in children with M4-M5 ANLL, 45:1–2, 6–7
 (3;17)(p21;p11) in Ph+ CML in CP, 47:202–204, 210
 (3;17)(q21;q21) in uterine sarcoma, 44:32, 33

- (3;18) in malignant mesothelioma (MM)
47:16, 27
(3;18)(p14;p11) in malignant
mesothelioma (MM) 47:11, 27
(3;19)(p11;q11) in nasopharyngeal
carcinoma, 49:32
(3;19)(p21;p12) from radiation-induced
tumors, 50:128
(3;19)(p21;p13) in nasopharyngeal
carcinoma, 49:32
(3;19)(q22;p13) in NHL, 47:78
(3;20)(p11;p11) in childhood
erythroleukemia, 49:27
(3;20)(q21;p13) in NHL, 47:78
(3;21)(p14;q22) in M2 ANLL, 45:28
(3;21)(q25;p11) in essential
thrombocythemia (ET), 49:60
(3;21)(q26;q22) in AML secondary to
PV, 44:275–276
(3;21)(q26;q22) in CMMoL secondary to
epithelioid hemangioendothelioma,
50:227–229
(3;21)(q26;q22) in patient with a solid
tumor, 50:227
(3;21)(q26;q22) in Ph+ CML, 50:227,
229
(3;21)(q26;q22) In Ph+ CML blast phase,
47:55–58; 50:227
(3;21)(q26;q22) in Ph+ CML chronic
phase, 50:227
(3;21)(q26-27;q22) in ANLL, 44:99,
101–104
(3;22)(q28;q11) atypical Ph+ CML,
44:181–183
(4;?)(p1;?) B cell growth factor (BCGF)
and lymphoma cytogenetics, 48:111
(4;?)(p15;?) in adenolymphoma, 46:37
(4;?)(p15;?) in nasopharyngeal
carcinoma, 49:32
(4;?)(p15.2;?) in Sézary syndrome,
45:235
(4;?)(p16;?) in NHL, 47:78
(4;4) in thyroid tumor, 44:127
(4;5)(q21;q33) from radiation-induced
tumors, 50:128
(4;6)(q31;p23) in a lipoma, 45:82
(4q6p) in breast cancer, 49:205
(4;6;13)(p16;q14;q13) in malignant
mesothelioma (MM), 47:11, 23
(4;7)(q21;q36) in uterine sarcoma, 44:32,
33
(4;7)(q35;p21) in a thyroid adenoma,
50:256
(4;8)(p16.1;q11.2) in peripheral T-cell
lymphoma (PTCL), 48:42
(4;8)(4pter→4p14::8q12→8pter) in
pleomorphic adenoma (PSA), 49:166
(4;8)(q13;p12) in ANLL, 44:173
(4;8)(q21;q22) from radiation-induced
tumors, 50:128
(4;8)(q21;q22) in angioimmunoblastic
lymphadenopathy (AILD), 50:19
(4;9)(p12;q11) alteration in RB1 gene in
leukemia, 49:18
(4;9)(p12;q34) from radiation-induced
tumors, 50:128
(4;9)(q21;q34) in childhood
erythroleukemia, 49:28
(4;10)(p11;q11) or (q11;p11) in
malignant mesothelioma (MM) 47:11,
23
(4;10)(p15;q21) in malignant
mesothelioma (MM) 47:24
(4;10)(q21;p15) in human malignant
melanoma (HMM) 48:240–241
(4;10)(q24;q23) in malignant
mesothelioma (MM) 47:11, 21
(4;11) and disease-free survival in ALL,
49:9
(4;11) and poor-risk subgroup in ALL,
49:8, 246
(4;11) in ALL, 44:57, 58; 46:248; 49:134
(4;11) in childhood ALL, 49:4
(4;11) in t-MDS, 49:135
(?;11) in thyroid tumor, 44:127
(4;11)(p15;q25) in angioimmunoblastic
lymphadenopathy (AILD), 50:19
(4;11)(q21;q23) and ataxia-telangiectasia
(A-T) gene locus, 46:1–6
(4;11)(q21;q23) and carcinogen exposure
in ALL, 49:133–135
(4;11)(q21;q23) in ALL, 44:69, 73; 49:3,
133–134
(4;11)(q21;q23) in children with M4-M5
ANLL, 45:1–2, 6–8
(4;11)(q21;q23) transposition of ets-1 in
AL, 50:199, 201
(4;11)(q31;q13) in malignant melanoma,
44:63, 64
(4;12)(q21;p13) in NHL, 47:78
(4;13)(q12;q12) in childhood
erythroleukemia, 49:28
(4;13)(q21;q32) in childhood
erythroleukemia, 49:28
(4;14)(p16;q22-q24) in angiofibroma,
45:168–169
(4;14)(q25;q32) from in vitro
radioresistance, 50:132
(4;16)(q11 or q12;p13) in Ph- CML,
47:205–206, 213
(4;17)(q13;p13) in uterine sarcoma,
44:32, 33
(4;18) polyploidization in colorectal
adenocarcinoma, 44:110
(4;18;13;9;22)(q12;q11;q14;q34;q11) in a
child with CML, 46:85

(4;22)(p;q) in fibrosarcoma, 48:196
 (4q22q) in breast cancer, 49:205
 (5;?)(p;?) in fibrosarcoma, 48:196
 (5;?)(p15;?) in fibrosarcoma, 48:196
 (5;?)(q33;?) TCR rearrangement in Sézary syndrome, 46:281–282
 (5;?)(q34;?) in hepatocellular carcinoma, 45:259
 (5;?)(q35;?) in SCC of the larynx, 44:211–212
 (5;5)(p15;q31) in CML blast phase, 47:56
 (5;6)(q31;p23) from radiation-induced tumors, 50:128
 (5;6)(q35;q15) in angiofibroma, 45:168–169
 (5;7)(q11;p11) in malignant myeloid disorders, 48:50
 (5;7)(q31;q11) in CML, 46:85
 (5;8)(q12;q11;p11) in SCC of the larynx, 44:211, 214
 (5;8;21)(q22;q22;q31) in ANLL, 44:173
 (5;9)(q12;q33) RCC, 45:199
 (5;9)(q13;q13) from radiation-induced tumors, 50:128
 (5;9)(q23;q34) from radiation-induced tumors, 50:128
 (5;9;12;22) in CML, 48:77, 79–80
 (5;10)(p15.3;q24) from radiation-induced tumors, 50:128
 (5;11)(p14;q23) in male breast cancer, 47:110
 (5;11)(q35;p13) in malignant mesothelioma (MM), 47:11, 14, 23
 (5;11)(q35;q13) in uterine sarcoma, 44:32, 33
 (5;12)(q13;q24) in childhood erythroleukemia, 49:28
 (5;12;22) in CML, 48:77, 80
 (5;13)(q31;q12) in T-cell ALL, 44:70
 (5;14)(p15.1;q31.2) in radio- or chemotherapy treated sperm, 46:255
 (5;14)(q24;q32) In ALL, 45:185
 (5;15)(q11;q11) In RCC, 45:199
 (5;16)(q11;q24) in synovial sarcoma, 50:277–578
 (5;17)(p11;p11) in MDS and ANLL, 46:173–175, 178, 180–181
 (5;17)(q11;p11) in t-MDS, 48:49–50
 (5;17)(q31;p13) from radiation-induced tumors, 50:128
 (5;18)(q11.2;q11.2) in synovial sarcoma, 50:277
 (5;19)(q13;q13) in a thyroid adenoma, 50:256
 (5;19)(q31;p13.1) from radiation-induced tumors, 50:128
 (5p21q) in breast cancer, 49:205
 (6;?)(p11;?) in nasopharyngeal carcinoma, 49:32

(6;?)(p22;p23) in nasopharyngeal carcinoma, 49:32
 (6;?)(p24;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19
 (6;?)(p24;?) in SCC of the larynx, 44:211–212
 (6;?)(p25;?) in SCC of the larynx, 44:211–212
 (6;?)(q25;?) in Hodgkin's disease (HD), 50:2, 4
 (6;?)(q27;?) in Hodgkin's disease (HD), 50:7
 (6;?)(6qter→6p23::?) in benign salivary gland pleomorphic adenoma, 44:256
 (6;?)(6qter→6q13::HSR(?)) in benign salivary gland pleomorphic adenoma, 44:256
 (6;6) in salivary gland pleomorphic adenoma (PSA), 46:60
 (6;6)(q23;q27) in PLL, 48:184
 (6;7)(q16;p15) in a thyroid carcinoma, 50:256
 (6;7)(q23;p22) in vocal cord carcinoma, 44:215
 (6;7)(q23;q22) in vocal cord carcinoma, 47:132
 (6;7)(q27;q11.2) in human malignant melanoma (HMM), 48:240–241
 (6;8)(p24;q21) in NHL, 47:78
 (6;8)(q26-q27;q13) in angiofibroma, 45:168, 172
 (6;8;21)(q21;q22;q22) in ANLL, 44:171, 173
 (6;9) in MDS, 46:158
 (6;9)(p23;q34) in M1 ANLL, 45:30, 47:213
 (6;9)(p32;q34) in childhood ANLL, 45:139–140
 (6;9;12)(q11;q12;q23) in esophageal carcinoma cell line, 45:105
 (6;10)(10;18)(p11-p12;p14-p15p11;q11-q12) in angiofibroma, 45:168
 (6;10)(p21.3;q22) in uterine leiomyoma, 47:181–182
 (6;10;13;18)(q23;q21;q14;q21) in childhood erythroleukemia, 49:28
 (6;11)(p11.2;p11.2) from radiation-induced tumors, 50:128
 (6;11)(q11;q14) in benign uterine leiomyoma, 44:5
 (6;11)(q31;q25) in benign uterine leiomyoma, 44:5
 (6;12)(p11.2;p13) in peritoneal mesothelioma, 46:136
 (6;12)(p21;p13) in breast cancer, 46:217, 224–225
 (6;12)(p22;q23) in angioimmunoblastic lymphadenopathy (AILD), 50:18
 (6;12)(q15;p13) in PLL, 45:153

- (6;13) in salivary gland pleomorphic adenoma (PSA), 46:59
(6;13)(6qter→6p21::13q12→13qter) in benign salivary gland pleomorphic adenoma, 44:256
(6;14)(p23;q21-22) in Sézary syndrome, 44:194
(6;14)(q21;q24) in metastatic ovarian adenocarcinoma, 45:223, 226; 48:250
(6;14)(q23;pter) in NHL, 47:78
(6;15) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93–96
(6;15)(p12;q11) in MDS, 44:273
(6;15)(p23;q12) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(6;15)(q16;q22) in esophageal carcinoma cell line, 45:105
(6;16)(p21;p13) in uterine leiomyoma, 49:54–55
(6;16)(q27;q12) after radiation therapy in Askin's tumor, 47:90, 92
(6;17)(p21;p12) in malignant mesothelioma (MM), 47:11, 26
(6;21)(q23;q24) in benign uterine leiomyoma, 44:5
(6;22)(p21;q11) masked Ph in CML, 47:223
(7;?) in bladder carcinoma, 49:145
(7;?)(p13;?) in mixed mesodermal tumor of ovary, 46:65, 67
(7;?)(p15;?) in Hodgkin's disease (HD), 50:7
(7;?)(p22;?) in Sézary syndrome, 45:235
(7;?)(q21;?) in NHL, 47:78
(7;?)(q32;?) in NHL, 47:78
(7;?)(q36;?) in ANLL, 44:173
(7;?)(q36;?) in NHL, 47:78
(7;7)(q32;q36) in T-cell ALL, 44:70, 72
(7;9) in bladder carcinoma, 49:145
(7;9)(p11-12;q11-13) in Sézary syndrome 45:235
(7;9)(q35;q33) in T-cell ALL, 44:71, 72
(7;9)(q36;q22) in ANLL, 44:172, 173
(7;9;22) in a child with CML, 46:85
(7;9;22)(q22;q34;q11) variant in CML, 47:199
(7;10) in Hodgkin's disease (HD), 50:2
(7;11)(p12;q13) in malignant melanoma, 44:63, 64
(7;11)(p13;p15) in M4 ANLL, 45:30
(7;11)(q32;q13) from radiation-induced tumors, 50:128
(7;12)(q11;q21) in adenolymphoma, 46:37
(7;12)(q36;q13) in angiofibroma, 45:168
(7;12)(q36;q13) in parathyroid adenoma, 48:227
(7;13)(p15;q11) in adenoid cystic carcinoma, 44:159
(7;13)(p22,q12) in a thyroid adenoma, 50:255–256
(7;13)(q11;q34) in de novo MDS, 44:21
(7;13)(q36;q14) PHA-stimulated lymphocytes in family member of ATL patient, 49:160–161
(7;14)(p11;q11) in angioimmunoblastic lymphadenopathy (AILD), 50:22
(7;14)(p15;q11) TCR rearrangement in Sézary syndrome, 46:281–282
(7;14)(p21-p22;q21-q22) in angiofibroma, 45:168–169
(7;14)(q35;q12) in malignant mesothelioma (MM), 47:11, 28
(7;15)(p12;p11) in ANLL in relapse, 44:174
(7;15)(p14;q21) in uterine leiomyoma, 47:181
(7;15)(q22;q24) in SCC of the larynx, 44:211, 213
(7;16)(p11;p13) in ANLL in relapse, 44:174
(7;17)(p11;p11) in MDS and ANLL, 173–175, 178, 180–181
(7;17)(p11;q11) in Ph+ CML in CP, 47:201, 203, 210–211
(7;17)(q22;q11) growth factors (rhGM-CSF) in MDS, 48:171, 174–175
(7;17;20)(q35;q21;33;p11.2) in peripheral T-cell lymphoma (PTCL), 48:42
(7;22) in thyroid tumor, 44:127
(7;22)(q11;q13) in fibrosarcoma, 48:196
(8;?)(p23;?) in NHL, 47:78
(8;?)(q22;?) from radiation-induced tumors, 50:128
(8;8)(p23;q12) in uveal malignant melanoma, 45:251
(8;9) in salivary gland pleomorphic adenoma (PSA), 46:59
(8;9)(p23;p22-21) in lymphoid malignancies, 45:125, 128
(8;9)(q12;p21) in lymphoid malignancies, 45:125
(8;9)(q12;p22) in pleomorphic adenoma (PSA), 49:166
(8;9)(q13;p24) in ALL, 45:127–128
(8;9)(q22;p24) in ALL, 45:127–128
(8;9)(q22;q31) in radio- or chemotherapy treated sperm, 46:255
(8;9)(q24;p21-13) in lymphoid malignancies, 45:125, 128
(8;11) in follicular small cleaved cell lymphoma, 48:199–200
(8;11)(p21;q13) in follicular small cleaved cell lymphoma, 48:199–200
(8;11)(q11;p11) in medulloblastoma, 47:146

- (8;12)(q24;q24) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (8;13) in salivary gland pleomorphic adenoma (PSA), 46:59
- (8;13)(q22;q21) in uterine sarcoma, 44:32, 33
- (8;13)(q23;q13) in childhood erythroleukemia, 49:28
- (8;14) in B-cell lymphoid malignancies, 49:219
- (8;14) in Burkitt-type PCL, 47:52
- (8;14) in NHL, 47:73; 49:266; 50:55
- (8;14) poor-risk subgroup in ALL, 49:8
- (8;14)(q21;q23) in malignant mesothelioma (MM), 47:24
- (8;14)(q22;q32) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
- (8;14)(q22;q32) in esophageal carcinoma cell line, 45:103, 106
- (8;14)(q23;q32) in American Burkitt lymphoma stage II, 48:275
- (8;14)(q24;q11) in T-cell ALL, 44:71–73; 49:3, 69, 71
- (8;14)(q24;q11) MYC and TCRA in T-ALL, 49:6–7
- (8;14)(q24;q24) in uterine leiomyosarcoma, 48:217, 220–222
- (8;14)(q24;q32) in American Burkitt lymphoma stage II, 48:275–276
- (8;14)(q24;q32) in B-ALL, 49:3
- (8;14)(q24;q32) in Burkitt-type ALL, 44:69; 45:69, 155; 46:93; 49:69, 72
- (8;14)(q24;q32) in NHL, 49:266
- (8;14)(q24;q32) MYC and IGH in B-ALL, 49:6
- (8;14)(q24.1;q11.2) from radiation-induced tumors, 50:128
- (8;14)(q24.1;q11.2) in T-ALL, 49:71
- (8;15;21)(q22;q21;q22) in ANLL, 44:171, 173
- (8;16)(q22;q24) mos gene in AML and DS, 49:168
- (8q16p) in breast cancer, 49:205–206, 208, 213
- (8;17)(p11;q11) in malignant mesothelioma (MM), 47:11, 23
- (8;17)(q11;q25) in Ph+ CML in CP, 47:202–204, 210
- (8;18)(q11;q21) after radiation therapy in Askin's tumor, 47:90–92
- (8;19;21)(q21;p13;q21-22) in ANLL, 44:171
- (8;21) in AML 44:169, 172–177, 45:28, 30; 46:185–187; 49:10
- (8;21) in de novo ANLL, 46:174
- (8;21) with –Y in M2 ANLL, 46:170
- (8;21)(q21;q11) in fibrosarcoma, 48:196
- (8;21)(q22;q11) in secondary APL with loss of Ph at relapse, 47:41–45
- (8;21)(q22;q22) appearance time of, 59:1490
- (8;21)(q22;q22) in AL, 49:177–183
- (8;21)(q22;q22) in de novo AML, 47:259, 262
- (8;21)(q22;q22) in M1, M2, and M4 ANLL, 44:99, 103, 104, 169
- (8;21)(q22;q22) in M2, 49:177–183
- (8;21)(q22;q22) in M2 and M4 ANLL, 50:103, 105–107
- (8;21)(q22;q22) in RAEB, 44:20, 18, 24
- (8;21)(q23;q21) in essential thrombocythemia, 49:60
- (8;21;5)(q22;q22;q31) in ANLL, 44:171
- (8;22) in Burkitt lymphoma, 46:93
- (8;22) poor-risk subgroup in ALL, 49:8
- (8;22)(q22.1;q13.3) in M2 and M4 in ANLL, 50:103, 105–107
- (8;22)(q24;q11) in B-ALL, 49:3
- (8;22)(q24;q11) in Burkitt lymphoma, 49:72
- (8;22)(q24;q11) in T-cell leukemia, 49:73
- (8;22)(q24;q11) MYC and IGL in B-ALL, 49:6
- (8;22)(q24.3;q11.2) from radiation-induced tumors, 50:128
- (8;22)(q24;q32) in NHL, 49:266
- (9;?) in NHL with del(7)(p14), 50:55
- (9;?) in thyroid adenoma, 48:227
- (9;?)(p13;?) in MDS and ANLL, 46:178
- (9;?)(p23;?) in metastatic ovarian adenocarcinoma, 45:226
- (9;?)(p23;?) in NHL, 47:78
- (9;?)(q34;?) c-myb gene in T-cell malignancies, 48:231
- (9;?)(q34;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (9;10)(q22;q26) in SCC of the larynx, 44:211, 214
- (9;10)(q32;q11.2) from radiation-induced tumors, 50:128
- (9;10;15;19;22) in CML, 46:87
- (9;11) in de novo ANLL, 46:174
- (9;11)(p21;q14) in T-cell ALL, 44:71, 72
- (9;11)(p22;q23) in acute monoblastic leukemia, 46:245
- (9;11)(p22;q23) in AMoL, 45:9
- (9;11)(p22;q23) in leukemia cells, 45:77, 46:6
- (9;11)(p22;q23) in M4-M5 ANLL, 45:1, 8
- (9;11)(p22;q23) transposition of ets-1 in AL, 50:199, 201–202
- (9;11)(q34;q21) in SCC of the larynx, 211, 214–215
- (9;11;22)(q34;q13;q11) variant of CML, 47:199

- (9;12)(p11-13;p11-12) in ALL, 49:3
(9;12)(p13-22;q13-15) in salivary gland pleomorphic adenoma (PSA), 44:156; 46:58
(9;12)(p22;q11) alteration in RB1 gene in leukemia, 49:18
(9;12)(q34;p12.3) from in vitro radioresistance, 50:132
(9;12;22)(q34;q11/q13;q11) variant in CML, 47:199
(9;12;22)(q34;q22;q11) in APL and in a case of CML BC with promyelocytic proliferation, 50:112
(9;13)(p21;q13-21) in ALL, 45:125, 128
(9;13)(q11;p11) in esophageal carcinoma cell line, 45:108
(9;13)(q34;q12) in SCC of the larynx, 47:132
(9;13)(q34;q12) in vocal cord carcinoma, 44:215
(9;14;22)(q34;q11;q11) atypical Ph+ CML, 44:181, 182
(9;15)(q13;q22) in childhood erythroleukemia, 49:28
(9;15)(q13;q22) in M2 AML with promyelocytosis, 45:28
(9;15)(q21;q21) in childhood erythroleukemia, 49:27
(9;15)(q22;q25-q26) in angiofibroma, 45:168
(9;15;22)(q31;q25;q12.2) in myxoid chondrosarcoma, 45:212
(9q17q) in breast cancer, 49:205
(9;18) in NHL with del(7)(p13), 50:55
(9;19)(p11;q11) in nasopharyngeal carcinoma, 49:32
(9;19)(p12;p13) in ANLL, 44:173
(9;22) and disease-free survival in ALL, 49:9
(9;22) and poor prognosis in ALL, 49:246
(9;22) in childhood ALL, 49:4
(9;22)(q22;q11) in myxoid chondrosarcoma, 45:212
(9;22)(q34;q11) ABL and BCR in pre-B, C-ALL, 49:6
(9;22)(q34;q11) alteration in RB1 gene in leukemia, 49:18
(9;22)(q34;q11) bcr in Ph+ ALL, 47:29, 33-34
(9;22)(q34;q11) DMS and +7 in BC of CML, 48:133-134
(9;22)(q34;q11) in ALL, 49:3
(9;22)(q34;q11) in CML, 45:28, 30; 45:69, 185, 193; 46:83, 85, 111, 46:170; 47:18, 56-57, 197, 203, 209, 219, 258-259; 48:75, 209, 211-212, 214
(9;22)(q34;q11) in CML, effects of G-CSF on mitotic index (Ph+), 47:278
(9;22)(q34;q11) in CML, effects of G-CSF on mitotic index (Ph-), 47:278
(9;22)(q34;q11) in CP of CML, 47:261
(9;22)(q34;q11) in Klinefelter syndrome with CML, 48:135
(9;22)(q34;q11) in secondary APL with loss of Ph at relapse, 47:41-44
(9;22)(q34;q11) late appearing Ph in ALL, 48:35-36
(9;22)(q34;q11) Ph+ CML in a child, 44:277
(9;22)(q34;q11) Ph+ CML in Hodgkin's disease (HD), 49:171-173
(9;22)(q34;q11) Ph+ cells in unstimulated PB, 47:261
(9;22)(q34;q11) Ph- cells in unstimulated PB after second BMT, 47:261
(9;22;17)(q34;q11;p12) in a child with CML after BMT, 46:83-87
(10;?)(p13-14;?) in Sézary syndrome, 45:235
(10;?)(q26;?) in NHL, 47:78
(10;10)(p15;q23) in endometrial adenocarcinoma, 47:157-158
(10;11) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
(10;11)(p11;q12) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
(10;11)(p14;q21) in T-cell ALL, 44:71
(10;11)(q11;p11) in Sézary syndrome, 45:235
(10;11)(q22;p15) in uterine sarcoma, 44:32, 33
(10;12)(q22;p13) from radiation-induced tumors, 50:128
(10;13)(q24;q14) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(10;14)(p11;q11) in esophageal carcinoma cell line, 45:103
(10;14)(q24;q11) in T-ALL, 49:3
(10;14)(q24;q11) TCL3 and TCRD in T-ALL, 49:6-7
(10;14;13)(q26;q22;q21.2) from radiation-induced tumors, 50:128
(10;15)(p11;p11) in nasopharyngeal carcinoma, 49:32
(10;15)(p15;q11.2) from radiation-induced tumors, 50:128
(10;16) in mixed and myxoid liposarcoma, 48:104
(10;16)(q11.2;p13.1) from radiation-induced tumors, 50:128
(10;16)(q26;q12) variant in CML, 47:199-200, 207

- (10;17)(q22.1;p13) in uterine leiomyosarcoma, 44:32; 47:95, 98; 48:221
- (10;18)(p14-p15;q11-q12) in angiomyoma, 45:168
- (10;18;19)(p11;q11;p12) in a child with CML after BMT, 46:83-87
- (10;19)(q22;p13 or q13) in follicular thyroid adenoma, 48:227
- (11;?) in bladder carcinoma, 49:145
- (11;?)(p?;?) in ANLL, 44:173
- (11;?)(p11 or p13) in carcinoma of the cervix uteri, 44:230, 233
- (11;?)(p11.2;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (11;?)(p12;?) in NHL, 47:78
- (11;?)(p14;?) in SCC of the larynx, 44:215
- (11;?)(p15;?) normal karyotype in leukemic cells before BMT, 47:255
- (11;?)(q;?) in fibrosarcoma, 48:196
- (11;?)(q13;?) in MDS and ANLL, 46:178
- (11;6;1)(q24;p25→q27;q31→q44) in esophageal carcinoma cell line, 45:105-106
- (11;12)(q21;q13) in salivary gland pleomorphic adenoma (PSA), 46:57
- (11;13) in salivary gland pleomorphic adenoma (PSA), 46:59
- (11;13)(p13;q14) in AMMoL, 45:261-262
- (11;13)(p15;q13-14) in synovial sarcoma, 50:277-278
- (11;13)(q14;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (11;14) in B-cell lymphoid malignancies, 49:219
- (11;14) in B-CLL, 45:144-145, 151; 48:183, 187, 189-190
- (11;14) in CLL/PLL, 45:153; 48:184
- (11;14) in NHL, 47:73; 49:266
- (11;14) in PLL, 45:155
- (11;14)(p11;q11) in T-cell ALL, 44:70, 72
- (11;14)(p11;q13) in carcinoma of the cervix uteri, 44:230
- (11;14)(p12;q13) in childhood erythroleukemia, 49:28
- (11;14)(p13;q11) in T-cell ALL, 44:70, 72; 49:3
- (11;14)(p13;q11) in TCRA/D T-ALL, 49:6-7
- (11;14)(p13;q13) in T-cell ALL, 45:262
- (11;14)(p15;q11) TAL1 and TCRD in T-ALL, 49:6-7
- (11;14)(q12;—?32) in NHL, 47:78
- (11;14)(q13;q11) in T-ALL, 49:69
- (11;14)(q13;q32) in B-CLL, 48:183, 187, 189-190
- (11;14)(q13;q32) in NHL, 49:266
- (11;14)(q13;q32) in PCL and MM, 47:51
- (11;14)(q13;q32) in PLL, 48:184
- (11;14)(q22;q32) in diffuse large cell NHL, 50:54
- (11;16) in endometrial malignant mixed müllerian tumors (MMMT) 46:52
- (11;16)(q13;q24) in leiomyoma, 44:4
- (11;17)(q23;q25) in children with ANLL, 45:1, 5-6, 8
- (11;18)(q23;q21) in SCC of the larynx, 47:132
- (11;19) in ALL, 44:73
- (11;19)(p11, q13) in SCC of the larynx, 44:211, 214
- (11;19)(q21;p13) in adenolymphoma, 46:38
- (11;19)(q23,p13) in ALL, 49:3
- (11;19)(q23;p13) in AMoL, 45:77
- (11;19)(q23;p13) transposition of ets-1 in AL, 50:199-204
- (11;20)(q13;q13) in SCC of the larynx, 44:211-212
- (11;21)(q23;q11.2) in MDS, 45:73, 79; 46:158
- (11;21)(q24;q11.2) in MDS at or near v-ets loci, 46:243-246, 249
- (11;22) in Ewing sarcoma, 47:1
- (11;22)(q23;q11) in Ewing sarcoma, 46:6; 47:89
- (11;22)(q23;q12) in Ewing sarcoma, 45:9
- (11;22)(q24;q12) after radiation therapy in Askin's tumor, 47:89-92
- (11;22)(q24;q12) in small cell osteosarcoma, 45:121-122
- (11;22)(q24;q12) primary skeletal Ewing sarcoma in DS, 47:61, 64-67
- (12;?) in salivary gland pleomorphic adenoma (PSA), 46:59
- (12;?)(p11;?) in MDS and ANLL, 46:178
- (12;?)(p12;?) in nasopharyngeal carcinoma, 49:32
- (12;?)(p13;?) in Hodgkin's disease (HD), 50:7
- (12;?)(p13;?) in MDS, 46:111
- (12;?)(p13;?) in MDS and ANLL, 46:178
- (12;?)(p13;?) in NHL, 47:78
- (12;?)(q13-15;?) in benign salivary gland pleomorphic adenoma, 44:253, 256
- (12;?)(q24;?) in NGL, 47:78
- (12;?;14)(p13;q13;?:q24) in salivary gland pleomorphic adenoma (PSA), 46:60
- (12;12)(p13;q11) in erythroleukemia (EL), 50:91-92
- (12;12)(q13;q22) in endometrial adenocarcinoma, 46:43-45
- (12;12)(q14;q24) in uterine leiomyoma, 49:54-55

- (12;13)(p13;q14) in BP of CML, 47:219, 221-223
(12p13q) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(12;14)(q13-15,q21-22) in benign uterine leiomyoma, 44:10
(12;14)(q14-15;q23-24) in leiomyoma, 47:97
(12;14)(q14-15;q23-24) in uterine leiomyoma, 44:32, 34; 45:63-66; 48:221-222
(12;14)(q15;q24) in uterine leiomyoma, 47:183-184
(12;14;14)(q22;q32;q23) with ring chromosomes in PCL, 47:49-50
(12;15) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93, 96
(12;15)(p11;q11) in esophageal carcinoma cell line, 45:103
(12;16) in liposarcoma, 47:1
(12;16)(q13;p11) in myxoid liposarcoma, 47:186; 48:101-105
(12;16)(q13.3;p11.2) in myxoid liposarcoma, 48:102-103, 105
(12q16p) in breast cancer, 49:205
(12;17)(p11;q11) in AML, 46:111
(12;17)(p12-13;q12) in ALL, 49:3
(12;17)(q13;p13) in B-PLL, 45:151
(12;17)(q21;q11) in B-PLL, 45:151
(12;18)(q13;q22) in ANLL, 44:173, 174
(12;18)(q15;q23) in salivary gland pleomorphic adenoma (PSA), 46:60
(12;20) in salivary gland pleomorphic adenoma (PSA), 46:60
(12;21)(p13;p11) normal karyotype in leukemic cells before BMT, 47:254
(12;21)(q13;q22) in leukemia secondary to MDS, 48:280
(12;22) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122
(12;22)(p13;q12) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122
(13;?) in bladder carcinoma, 49:145
(13;?)(p11.2;?) in nasopharyngeal carcinoma, 49:32
(13;?)(13pter→13q34::?) in benign salivary gland pleomorphic adenoma, 44:256
(13;?)(q34;?) in NHL, 47:78
(13;13)(q31;q34) in CLL, 48:184
(13;14) in ANLL, 45:194
(13q14q) marker chromosomes in lung cancer cell line, 49:190-191
(13;15) in atypical lymphoid leukemia, 45:194
(13;15) in PLL, 45:194
(13;15)(p11;q11) in adenocarcinoma of the prostate, 48:86
(13;15)(p11;q11) in esophageal carcinoma cell line, 45:107, 112
(13;15)(q11;p11) in esophageal carcinoma cell line, 45:106, 109
(13;15)(q11;p12) in esophageal carcinoma cell line, 45:103
(13;15)(q11;q26) after radiation therapy in Askin's tumor, 47:90, 92
(13;16) in Hodgkin's disease (HD), 50:2
(13;17)(cen;cen) in ANLL in relapse, 44:173
(13;17)(q32;q21) in SCC of the larynx, 44:211, 214
(13;18)(p11;p11) in human malignant melanoma (HMM), 48:240-241
(13;19)(q14;q13.4) in peripheral T-cell lymphoma (PTCL), 48:42
(13;20)(q14;q13) in SCC of the larynx, 44:211-212, 214-215
(13;21)(p11;p11) in lymphoma, 44:279-280
(13;21)(p11;q11) in esophageal carcinoma cell line, 45:108
(13;22)(q32;q13) from radiation-induced tumors, 50:128
(14;?)(q11;?) TCR rearrangement in Sézary syndrome, 46:281-282
(14;?)(q32;?) normal karyotype in leukemic cells before BMT, 47:255
(14;?)(q32;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
(14;?)(q32;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19
(14;?)(q32;?) in Hodgkin's disease (HD), 50:7
(14;?)(q32;?) in NHL, 47:78
(14;14)(p11;q11) in NHL, 47:78
(14q;14q) in carcinoma of the cervix uteri, 44:231
(14;14)(q11.2;q32) in T-ALL, 44:47, 51, 52
(14;15) in a SV40 virus-transformed tumorigenic human cell line, 50:231
(14;15)(p11;p11) in RAEB-t, 44:23
(14;15)(p11;q11) in adenocarcinoma of the prostate, 48:86
(14;15)(q11;p11) in esophageal carcinoma cell line, 45:109
(14q15q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 241-244
(14;16)(p11;p11) alteration in the RB1 gene in leukemia, 49:18
(14;16)(p13;q13) from radiation-induced tumors, 50:128

- (14;16)(q24;p13) in SCC of the larynx, 44:211
- (14;18) in B-cell lymphoid malignancies, 49:219
- (14;18) in B-CLL, 45:151
- (14;18) in diffuse large-cell lymphoma, 46:91
- (14;18) in follicular small cleaved cell lymphoma, 48:199–200
- (14;18) in NHL, 47:73; 49:266; 50:55
- (14;18)(q11.2;p13) recurrent marker in peripheral T-cell lymphoma (PTCL) 48:45
- (14;18)(q32;q21) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111, 113
- (14;18)(q32;q21) in follicular lymphoma, 45:127
- (14;18)(q32;q21) in follicular small cleaved cell lymphoma, 48:199–200
- (14;18)(q32;q21) in NHL, 47:78; 49:266
- (14;18)(q32?;?q21) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (14;18)(q32;q34) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (14;19) in CLL, 49:219, 221–222
- (14;19)(q32;q13) in B-cell lymphoma, 45:152
- (14;19)(q32.3;q13.1) in B-CLL, 49:219, 221–222
- (14;21) in APL, 45:194–195
- (14;21) in salivary gland pleomorphic adenoma (PSA), 46:58
- (14;21)(p11;q11) in esophageal carcinoma cell line, 45:105, 108
- (14q21q) in lung squamous cell carcinoma, 49:41–42, 45
- (14;22) in thyroid tumor, 44:127
- (14;22)(q13;p11) in breast cancer, 46:224
- (14;22)(q32;q11) in ALL, 49:3
- (14q22q) in breast cancer, 49:205
- (15;?)(p11;?) in NHL, 47:78
- (15;?)(q15;?) TCR rearrangement in Sézary syndrome, 46:281–282
- (15;?)(15qter→15q11::?) in benign salivary gland pleomorphic adenoma, 44:256
- (15q15q) in breast cancer, 49:205
- (15q15q) in lung squamous cell carcinoma, 49:40, 42
- (15;16) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93–96
- (15;16)(q21;q13) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (15;17) in APL and in a case of CML BC with promyelocytic proliferation, 50:109–115
- (15;17) in de novo ANLL, 46:174, 180; 47:262
- (15;17) in M3 AL, 45:128
- (15;17) in M3 leukemia and in CML in promyelocytic blast crisis, 47:57
- (15;17)(q11.2;p11.2) from radiation-induced tumors, 50:128
- (15;17)(q22;q11–q12) in ANLL, 44:103, 104
- (15;17)(q22;q12) in APL, 45:28, 30
- (15;17)(q22;q12) in APL, 45:194
- (15;17)(q22;q12) in APL and in a case of CML BC with promyelocytic proliferation, 50:109–115
- (15;17)(q22;q12-21) in APL and in a case of CML BC with promyelocytic proliferation, 50:112
- (15;19)(q22;q24) in esophageal carcinoma cell line, 45:103
- (15;20)(p11;q11) in testicular and ovarian germ cell tumor cell lines (GCT) 50:67–69, 71–72
- (15;20)(q21;q13.3) in childhood erythroleukemia, 49:27
- (15;21)(q21-q22;q22) in ANLL, 44:99, 102–104
- (15;22)(p11;q11) in esophageal carcinoma cell line, 45:106, 109
- (15;22)(p11;q11) in nasopharyngeal carcinoma, 49:32
- (15;22)(q15;p13) from radiation-induced tumors, 50:128
- (15;22)(q21;q11) in malignant mesothelioma (MM), 47:11, 23
- (16;?)(p13;?) in uterine leiomyosarcoma, 48:217, 220–221
- (16;?)(q24;?) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
- (16;?)(q24;?) in NHL, 47:78
- (16;?)(q24;?) in SCC of the larynx, 44:212, 215
- (16;?)(q24;?) in uterine leiomyosarcoma, 48:217, 220–221
- (16;16)(p13;q22) in myelomonocytic leukemia, 49:246
- (16p17q) in breast cancer, 49:205–206, 210, 213
- (16;19)(p11.2;p11) from radiation-induced tumors, 50:128
- (16;20)(p12;q13) in T-ALL, 49:241, 245–246
- (16;21)(p11;q22) in M1 ANLL, 47:139–140
- (16;21)(p11;q22) in M2 ANLL, 45:28
- (16;22)(p13;q11) atypical Ph+ CML, 44:181, 182

- (16;22)(q21;qter) in breast cancer, 49:206
(17;?) in bladder carcinoma, 49:145
(17;?)(p11;?) in RAEB-t, 44:23
(17;?)(p11-12;?) in MDS and ANLL, 46:173
(17;?)(p13;?) in nasopharyngeal carcinoma, 49:32
(17;?)(p13;?) in NHL, 47:78
(17;?)(q11;?) in adenolymphoma, 46:37
(17;?)(q23;?) in Hodgkin's disease (HD), 50:7
(17;?)(q24;?) in NHL, 47:78
(17;18)(q11.2;q23) in AMMoL patient, 48:125-128
(17;19)(q23;p13) in ALL, 47:258
(17;20)(p13;p11.2) from radiation-induced tumors, 50:128
(17;22) in thyroid tumor, 44:127
(17;22)(p13;q12) atypical Ph+ CML, 44:181, 182
(18;?) in a SV40 virus-transformed tumorigenic human cell line, 50:231, 239
(18;?) polyploidization in colorectal adenocarcinoma, 44:110
(18;?)(p?;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242, 244
(18;?)(q;?) in essential thrombocythemia, 49:60
(18;?)(q23;?) in diffuse large cell NHL, 50:54
(18;19)(q21;q13) in SCC of the head and neck, 47:131-133
(18;22)(q12;q11) in meningioma, 45:239
(19;?)(p13;?) in NHL, 47:78
(19;?)(p13;?) in uterine leiomyosarcoma, 48:217, 220-221
(19;?)(p13.3;) in a SV40 virus-transformed tumorigenic human cell line, 50:243-244
(19;?)(p22;?) in SCC of the larynx, 44:211-212
(19;?)(q13;?) in Hodgkin's disease (HD), 50:7
(19;?)(q13;?) in NHL, 47:78
(19;?)(q35;?) normal karyotype in leukemic cells before BMT, 47:255
(19;?)t(19;?) structural rearrangement in colorectal adenocarcinoma, 44:112
(19;2;13)(q13;p13;q21) in esophageal carcinoma cell line, 45:108
(19;21)(q12;p13) from radiation-induced tumors, 50:128
(20;?) in thyroid tumor, 44:127
(20;?)(20pter→?20q13::?) in male breast cancer, 47:108
(20;?)(p12;?) in NHL, 47:78
(20;?)(q13;?) in subcutaneous leiomyosarcoma of the knee, 48:217, 220
(21;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239
(21;?)(p11.2;?) in nasopharyngeal carcinoma, 49:32
(21;?)(q22;?) in AML, 46:111
(21;11)(q22.3;q23q14.2) rearranged and amplified ets-1 in a lymphoma, 50:201
(21;21)(p11;q11) in CML, 45:193, 195
(21;21)(p11;q11) in essential thrombocytosis and myelofibrosis, 45:194-195
(21;21)(p11;q11) in t-MDS, ANLL and RAEB, 48:51
(21;21)(p11;q11) in t-MDS progressed to "frank" leukemia, 48:50
(21;22) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122
(21;22) in salivary gland pleomorphic adenoma (PSA), 46:58
(21;22)(p11;q11) in esophageal carcinoma cell line, 45:106, 109
(22;?)(p11;?) in nasopharyngeal carcinoma, 49:32
(22;?)(q12;?) in hepatocellular carcinoma, 45:259
(22;?)(q13;?) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
(22;?)(q13;?) in NHL, 47:78
(22;22)(q11;q13) variant Ph translocation in CML, 47:199; 48:209-212, 214-215
(22;22)(q37;q11) variant Ph translocation in CML, 47:198-199
Trisomy
in AILD, 44:77, 50:15
in breast cancer, 46:217
in cervical cancers, 44:229
in CIS of testis, 46:75
in endometrial tumors, 46:41
in Hodgkin disease, 50:1
in large bowel cancer, 44:83, 107; 46:143
in lung tumors, 48:203
in lymphoma, 45:125; 47:73
in MDS, 46:173
in mesothelioma, 47:1
in renal cell carcinoma, 45:197
in T-ALL, 44:69
in thyroid adenomas, 44:217
in uterine tumors, 46:41
partial trisomies in tuberous sclerosis, 45:161
+3 and +12 in cold agglutinin disease, 46:89
+3 in male breast cancer, 47:107

- +4 in ANLL with hand-mirror cells, 45:265
- +4 in biphenotypic acute leukemia, 47:265
- +7 and +13 in colon polyps, 49:249
- +7 in atherosclerotic plaque, 47:273
- +7 in bladder cancer, 50:9
- +7 in gliomas, 47:141
- +7 in renal tumors, significance, 49:259
- +8 in ANLL, 45:1, 67
- +8 in CML, 47:197
- +8 in MDS, 44:15; 46:125, 157
- +12 in CLL, 45:143
- +12 in leiomyomas, 45:63
- +13 in ALL, 45:139
- +13 in MDS (RAEB), 48:179
- +14 in MDS, 49:113
- +19 in CML, 47:197
- +20 in liver tumor, 47:243
- +21 (transient) in MPD, 48:259
- Tuberous sclerosis**
 - chromosomes in blood and skin cells and in angiofibromas, 45:161
 - cytogenetic studies, 45:161
 - 1, 3, 7, 10 and 15, 45:161
- Tumors**
 - bladder, 46:129
 - brain (meningiomas), 45:41; 47:141
 - brain (pontine astrocytoma), 47:101
 - breast, 46:217
 - cervical (uterine), 44:229
 - endometrial, 46:41; 47:155
 - in Ewing sarcoma, 47:61
 - kidney, 45:197
 - large bowel, 44:107; 46:143
 - larynx, 44:209
 - leiomyosarcoma, 44:27; 47:89; 48:217
 - liver, 47:243
 - lung, 48:203
 - mesodermal, mixed; 44:27
 - myomas, 44:1; 45:63; 47:89; 47:179; 49:51
 - neurinomas, 45:55
 - ovary, 44:223; 45:49, 223; 46:65, 71, 115; 48:53, 243
 - salivary glands, 44:153; 46:35, 55
 - testis, 46:75; 48:1, 143
 - thyroid, 44:119, 217; 50:249
 - uterine, 44:1; 45:63; 46:41; 47:89, 155, 179; 48:217; 49:51
 - Wilms tumor, 45:35
- Uterus**
 - cervical tumors, 44:229
 - chromosome 10 in endometrial cancer, 47:155
 - endometrial malignancies, 46:41; 47:155; 50:189
- leiomyoma, 44:1; 45:63; 47:89, 179; 49:51**
- leiomyosarcoma, 44:27; 47:89; 48:217**
- malignant mixed müllerian tumor, 46:41**
- mesodermal tumor, 44:27**
- sarcoma, 44:27**
- SV40-transformed cell line and karyotype evolution, 50:231**
- tumors, 44:1; 46:41; 47:155, 179; 49:51; 50:189**
- Virus(es)**
 - from vulvar neoplasia, 44:243
 - integration into 12q of human papillomavirus DNA, 44:243
 - papillomavirus (human, type 16), 44:243
- von Hippel-Lindau disease**
 - chromosomes in kidney tumors, 49:125
 - kidney tumors in, 49:125
 - renal adenoma and, 49:125
 - renal cell carcinoma, 49:125
- Warthin's tumor**
 - adenolymphomas, 46:35
 - chromosomes in, 46:35
 - of salivary gland, 46:35
- Wiedemann-Beckwith syndrome**
 - Wilms tumor in, 45:35
- Wilms tumor**
 - chromosomes, 45:35
 - in Wiedemann-Beckwith syndrome, 45:35
 - t(X;20) in, 45:35
- X chromosome**
 - FRAXD at Xq27.2, 49:137
 - fra(X)(q28) in esophageal cancer, 45:269
 - in large bowel cancer, 44:107
 - loss in AILD, 44:77; 50:15
 - t(X;12) in lipoma, 49:235
 - two identical X chromosomes in breast cancer cell lines, 46:271
- X-linked lymphoproliferative disease (XLP), 47:163**
 - +X and -X in AILD, 50:15
 - X in M2 with t(8;21), 44:169
 - X in renal tumors, significance, 49:259
 - X in urothelial tumors and disease course, 50:97
- X-linked lymphoproliferative disease (XLP)**
 - family with, 47:163
 - mapping of gene, 47:271
 - partial Xq25 deletion, 47:163
- X-ray; see Radiation exposure**
- XY male**
 - with ALL, 49:225

Y chromosome

- molecular studies of Y loss, 45:41
- XYY male with ALL, 49:225
- +Y in esophageal cancer, 45:269
- Y and thorotраст, 45:13
- Y in AILD, 50:15
- Y in MDS, 44:15; 46:157
- Y in meningiomas, 45:41
- Y in monocytic leukemia, 46:99
- Y in M2 with t(8;21), 44:169
- Y in M4, 44:99

-Y in neurinoma, 45:55

- Y in renal tumors, significance, 49:259**
- Y in urothelial tumors and disease course, 50:97**
- Y in Warthin's tumor, 46:35**

Yolk sac tumor

- chromosomes in, 44:223**
- DNA studies in, 44:223
- metastatic, 44:223
- ovarian, 44:223
- testicular, 48:143

